PROTOCOL: TAK -620-1020
TITLE: A Phase 1, Open- label, Randomized, Cross -over Study  to Evaluate the 
Pharmacokinetics, Safety, and Tolerabilit y of a Single Oral Dose of 
Maribavir Administered in Healthy  Japanese Subjects Compared with 
Matched, Healthy , Non -Hispanic, Caucasian Subjects and to Assess 
Dose -Proportionality  of 3 Doses of Maribavir in the Japanese Subjects
DRUG: TAK -620 (Maribavir)
IND: 051001
EUDRACT NO.: Non-EUDRACT
SPONSOR: Shire ViroPharma LLC (Shire, [and affiliates]); Shire is a wholly owned 
subsidiary  of Takeda Pharmaceutical Company  Limited 300 Shire Way , 
Lexington, MA 02421 USA 
PRINCIPAL/
COORDINATING
INVESTIGATOR:, DO, FACP
PROTOCOL 
HISTORY:Protocol Amendment 1: 08 July 2020
Original Protocol: 03 April 2020
This document contains confidential and proprietary information of Shire and is disclosed pursuant to confidentiality 
and non-disclosure obligations. This information should be used solely for the purposes for which it was provided 
and should not be copied, shared w ith, or disclosed to any third party without the express written consent of Shire.

Shire CONFIDENTIAL Page 7
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
EMERGENCY  CONT ACT IN FORMA TION
In the event of a serious adverse event (SAE), the investigator must fax or e -mail the "Shire 
Clinical Study  Adverse Event Form for Serious Adverse Events (SAEs) and Non -serious adverse 
events (AEs) as Required by  the Protocol" within 24 hours to the Shire Global Drug Safet y 
Department. The fax number and e -mail address are provided on the form (sent under separate 
cover). A cop y of this form must also be sent to the contract research organization (CRO) 
(asapplicable) and Shire Medical Monitor using the details b elow.
For protocol -or safety-related questions the investigator must contact the Shire Medical 
Monitor:
, MD, PhD, MPH
Shire Study  Medical Monitor
Telephone: 
Cell phone:  (24- hour coverage)
E-mail: 
For protocol -or safety
-related questions or concerns outside of normal business hours, the 
investigator must contact the Shire Medical Monitor.

Shire CONFIDENTIAL Page 8
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
PRODUCT QUALITY  COMP LAINTS
Investigators are required to report investigation al product quality  complaints or non -medical 
complaints to Shire within 24 hours. If requested, defective product(s) will be returned to the 
sponsor for inspection and anal ysis.
A product quality  complaint includes any  instances where there is an allegation or report relating 
to Shire licensed or investigational products, received in writing, electronically , or orall y, which 
indicates an impact to a product’s strength, identity, safet y, purit y, or quality, or which suggests 
that the product did not meet the criteria defined in the regulatory  applications, licenses, or 
marketing authorizations for the product. Examples of investigational product quality  complaints 
include, but are not limited to, the following:
Unit issues Bottle/vial fill shortage or overage
Tablet damaged/broken
Vial cracked/brokenProduct discoloration
Labeling Label missing
Leaflet or Instructions For Use 
(IFU) missing 
Label illegibleIncomplete, inaccurate, or 
misleading labeling
Lot number or serial number missing
Packaging Damaged packaging (eg, secondary , 
primary , bag/pouch)
Tampered seals
Inadequate or faulty  closureMissing components within package
Foreign 
materialContaminated product
Particulate in bottle
Particulate in packaging
Please report the product quality  complaint using the “Product Quality  Complaint Data 
Collection Form” via the email address:

Shire CONFIDENTIAL Page 9
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
TABLE OF  CONTENTS
PROTOCOL  SIGNATURE P AGE .................................................................................................2
SUMMARY OF CHANGES FROM PREV IOUS PROTOCOL  VERSIO N..................................3
EMERGENCY CONTACT I NFORMATION ................................................................................7
PRODUCT QUALITY COMP LAINTS ..........................................................................................8
TABLE OF CONTENTS ................................................................
.................................................9
LIST OF TABLES .........................................................................................................................12
LIST OF FIGURES .......................................................................................................................12
LIST OF APPENDICES ................................................................................................................12
ABBREVIAT IONS .......................................................................................................................13
STUDY SYNOPSI S ......................................................................................................................15
1.BACKGROUND INFORMATI ON.......................................................................................28
1.1 Indication and Current Treatment Options ...............................................................
28
1.2 Product Background .................................................................................................29
1.2.1 Preclinical Information ..........................................................................................29
1.2.2 Clinical I nformation ...............................................................................................29
1.2.3 Pharmacokinetics and metabolism.........................................................................29
1.2.4 Efficacy ................................................................
..................................................30
1.2.5 Safety .....................................................................................................................31
1.3 Risk/Benefit and Ethical Assessment.......................................................................32
1.4 Compliance Statement ..............................................................................................32
2.STUDY OBJECTIVES AND PURPOSE ................................
..............................................33
2.1 Rationale for the Study .............................................................................................33
2.2 Study  Objectives ......................................................................................................33
2.2.1 Primary  Objective ..................................................................................................33
2.2.2 Secondary  Objectives .............................................................................................33
2.2.3 Exploratory  Objective ............................................................................................33
3.STUDY DESIGN ...................................................................................................................34
3.1 Study  Design and Flow Chart ..................................................................................34
3.2 Maximum Duration of Participation and Study  Completion ................................ ...38
3.3 Sites and Regions .....................................................................................................38
4.STUDY POPUL ATION.........................................................................................................39
4.1 Inclusion Criteria
................................ ................................ ................................ ......39
4.2 Exclusion Criteria ................................ ................................ ................................ .....39
4.3 Restrictions ................................ ................................ ................................ ............... 41
4.4 Reproductive Potential ................................ ................................ ............................. 41
4.4.1 Female Contraception ................................ ................................ ............................ 41
Shire CONFIDENTIAL Page 10
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
4.4.2 Male Contraception ................................................................................................42
4.5
Discontinuation of Subjects .....................................................................................42
4.5.1 Reasons for Discontinuation ..................................................................................43
4.5.2 Subjects ‘L ost to Follow -up’ Prior to Last Scheduled Visit ..................................43
5.PRIOR AND CONCOMITAN T TREATMENT ...................................................................44
5.1 Prior Treatment ........................................................................................................44
5.2 Concomitant Treatment ............................................................................................44
5.2.1 Permitted Treatment ...............................................................................................44
5.2.2 Prohibited Treatment .............................................................................................44
6.INVESTIGAT IONAL PROD UCT ........................................................................................45
6.1 Identity  of Investigational Product ...........................................................................45
6.1.1 Blinding the Treatment Assignment ......................................................................45
6.1.2 Unblinding the Treatment Assignment ..................................................................45
6.2 Administration of I nvestigati onal Product(s) ...........................................................45
6.2.1 Allocation of Subjects to Treatment ......................................................................45
6.2.2 Dosing ....................................................................................................................46
6.2.3 Administration .......................................................................................................46
6.3 Labeling, Packaging, Storage, and Handling ...........................................................46
6.3.1 Labeling .................................................................................................................46
6.3.2 Packaging ...............................................................................................................47
6.3.3 Storage ...................................................................................................................47
6.4 Drug Accountability .................................................................................................47
6.5 Subject Compliance ..................................................................................................48
6.6 Retention of Bioavailability  and Bioequivalence Testing Samples .........................48
7. STUDY PROCEDURES........................................................................................................49
7.1 Study  
Schedule .........................................................................................................49
7.1.1 Screening Period ................................
....................................................................49
7.1.1.1 Screening Failure ....................................................................................49
7.1.1.2 Rescreening of Subjects ................................ ................................ ......... 49
7.1.2 Predose Assessments ................................ ................................ ............................. 50
7.1.3 Treatment Periods ..................................................................................................50
7.1.3.1 Treatment Period 1 (Non -Hispanic, Caucasian Subjects) ......................50
7.1.3.2 Treatment Period 1 (Japanese Subjects) .................................................50
7.1.3.3 Treatment Period 2 (Japanese Subjects) .................................................50
7.1.3.4 Treatment Period 3 (Japanese Subjects) ................................ ................. 50
7.1.4 Follow -up Period (All Subjects) ................................ ................................ ............ 50
7.1.5 Additional Care of Subjects After the Study ................................ ......................... 51
7.2 Study  Evaluations and Procedures ................................ ................................ ........... 51
Shire CONFIDENTIAL Page 11
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
7.2.1 Demographic and Other Baseline Characteristics .................................................51
7.2.1.1 Height and Weight ................................
.................................................51
7.2.2 Safety .....................................................................................................................51
7.2.2.1 Medical and Medication History ............................................................51
7.2.2.2 Physical Examination (Including Height and Weight) ..........................52
7.2.2.3 Adverse Event Collection.......................................................................52
7.2.2.4 Vital Signs ..............................................................................................
52
7.2.2.5 Electrocardiogram ..................................................................................54
7.2.2.6 Clinical L aboratory  Tests .......................................................................55
7.2.2.7 Pregnancy  Test .......................................................................................56
7.2.2.8 Drug and Alcohol Screen .......................................................................56
7.2.2.9 Serology  Screen ......................................................................................57
7.2.3 Pharmacokinetic Procedures ................................
..................................................57
7.2.3.1 Blood Sample Collection and Handling Procedures ..............................57
7.2.3.2 Plasma Drug Assay  Methodology ..........................................................57
7.2.4 Volume of Blood to be Drawn from Each Subject ................................................57
8.DATA MANAGEMENT AND STATISTICAL METHODS...............................................59
8.1 Data Collection ................................................................
.........................................59
8.2 Clinical Data Management .......................................................................................59
8.3
Data Handling ..........................................................................................................59
8.4 Statistical Analy
sis Process ......................................................................................59
8.5 Planned Interim Anal ysis, Adaptive Design, and Data Monitoring Committee ......60
8.6 Study  Population ......................................................................................................60
8.7 Pharmacokinetic Analy ses................................
.......................................................60
8.7.1 Pharmacokinetic Endpoint(s).................................................................................60
8.7.1.1 Statistical Analy sis of Pharmacokinetic Parameters ..............................61
8.8 Safety  Anal yses................................................................
........................................62
8.9 Sample Size Calculation and Power Considerations................................ ................ 63
9.REFERENCES ................................ ................................ ................................ ....................... 64
10.PROTOCOL  HISTORY ................................ ................................ ................................ ......... 66
Shire CONFIDENTIAL Page 12
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
LIST  OF TABLES
Table 1 Schedule of Assessments for Subjects of Japanese Descent .........................21
Table 2 Detailed Schedule of Assessments for Subjects of Japanese Descent 
for Day s1 and 2 of Treatment Period 1 ........................................................23
Table 3 Detailed Schedule of Assessments for Subjects of Japanese Descent 
for Day s1 and 2 of Treatment Period 2
........................................................24
Table 4 Detailed Schedule of Assessments for Subjects of Japanese Descent 
for Day s1 and 2 of Treatment Period 3 ........................................................25
Table 5 Schedule of Assessments for Non
-Hispanic, Caucasian Subjects .................26
Table 6 Detailed Schedule of Assessments for Non -Hispanic Caucasian 
Subjects for Day s1 and 2 of Treatment Period 1..........................................27
Table 7 Volume of Blood to be Drawn from Each Subject ........................................58
LIST  OF FIGURES
Figure 1 Study  Design Flow Chart ................................
..............................................37
LIST  OF APPENDICES
Appendix 1 Regulatory , Ethical, and Study  Oversight Considerations ............................67
Appendix 2 Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting .........................................................74
Shire CONFIDENTIAL Page 13
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
ABBREVIA TIONS
AE adverse event
AUC area under the curve
AUC last area under the curve from the time of dosing to the last measurable 
concentration
AUC 0-inf area under the curve extrapolated to infinity , calculated using the observed 
value of the last non -zero concentration
AUC 0-inf%extrap The percent of AUC 0-infextrapolated, calculated by (1 -AUC last/AUC 0-inf)*100
-HCG beta-human chorionic gonadotropin
BMI body  mass index
BID twice dail y
Cmax maximum concentration 
CL/F oral clearance 
CMV cytomegalovirus
CRA clinical research associate
CRC clinical research center
CRF case report form
CRO contract research organization
CV coefficient of variation
CV% percent coefficient of variation
CYP cytochrome P450
DNA deox yribonucleic acid
EC Ethics Committee
ECG electrocardiogram
EMA European Medicines Agency
EU European Union
GCP Good Clinical Practice
GI gastrointestinal
HBsAg hepatitis B surface antibody
HCV hepatitis C virus
HDPE high densit y polyeth ylene
HIPAA Health Insurance Portability  and Accountability  Act
HIV human immunodeficiency virus
HSCT hematopoietic stem cell transplants 
IB Investigator’s Brochure
Shire CONFIDENTIAL Page 14
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
IP investigational product (investigational drug)
IRB Institutional Review Board
IV intravenous
z first order rate constant associated with the terminal (log linear) portion of the 
curve
P-gp P-glycoprotein
PK pharmacokinetics
PT preferred term
QTc corrected QT interval
QTcF The corrected QT interval by  Fredericia Correction Formula
SAE serious adverse event
SAP statistical analy sis plan
SOT solid organ transplant
SUSAR Suspected Unexpected Serious Adverse Reaction 
t1/2 terminal half -life
TEAE treatment -emergent adverse event
TID 3 times daily
Tlag Delay  between the time of dosing and time of appearance of drug
(investigational) in plasma in the employ ed sampling scheme
tmax time of maximum observed concentration sampled during a dosing interval
TSH thyroid- stimulating hormone
US United States
US FDA United States Food and Drug Administration
US CFR
United States Code of Federal Regulations 
Vdz/F Apparent volume of distribution 
Shire CONFIDENTIAL Page 16
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Rationale:
This study is being conducted to compare the PK, safety, and tolerability of maribavir administered as a single 
oral dose in healthy adult subjects of Japanese descent and matched, healthy, adult non -Hispanic, Caucasian 
subjects. In addition, this study will assess the dose -proportionality and PK of maribavir in healthy, adult 
subjects of Japanese descent.
In accordance w ith the ICH -E5, this study is designed to evaluat e whether there is any ethnic difference in PK 
and safety of maribavir between Japanese and non -Japanese subjects. These data w ill inform the bridging of 
safety and efficacy data from non -Japanese subjects to the Japanese population.
The results from this study will be utilized to guide dose selection for a future Phase 3 study in Japanese 
transplant patients with cytomegalovirus (CMV) infection.
Investigational product, dose, and m ode of administration:
Maribavir is the investigational product (IP) for this study and w ill be administered orally as a single 200 mg 
(1×200 mg tablet, current Phase 3 formulation), 400 mg (2×200 mg tablets), and 800 mg (4×200 mg tablets) 
dose.
Methodology:
This is a Phase 1, open -label, randomized, crossover, partially fixed sequence, single- center study to evaluate 
the PK profile, safety, and tolerability of maribavir administered in healthy, adult subjects of Japanese descent 
and matched, healthy, adult, non -Hispanic, Caucasian subjects. The non -Hispanic, Caucasian subjects will 
receive a single oral dose of 400 mg maribavir on Day 1. For this cohort there will be one treatment period 
(Table5and Table 6).The Japanese subjects will receive 3 doses of maribavir separated by a 72 -hour washout 
period betw een doses: in Treatmen t Period 1 on Day 1, they will receive a single oral dose of 400 mg of 
maribavir; in Treatment Period 2 and Treatment Period 3 on Day 1, they will be randomized to receive a single 
oral dose of either 200 mg follow ed by  800 mg of maribavir or vice versa ( Table 1, Table 2, Table3, and 
Table 4).A total of 24 subjects will be enrolled: 12 subjects of Japanese descent and 12 non-Hispanic, 
Caucasian subjects. Non -Hispanic, Caucasian subjects w ill be matched to Japanese subjects based on age 
(years), sex, a nd BMI ( 15%). 
The study will comprise a 28 -day screening period, Treatment Period 1 for the non -Hispanic, Caucasian cohort, 
and Treatment Periods 1, 2, and 3 for the subjects of Japanese descent. There w ill be a post -treatment follow -up 
telephone call at 7 (±4) days after the last dose of IP for all subjects. Screening will occur within 28 days of the 
first dose. Subjects w ill be admitted to the clinical research center (CRC) on Day -1. All subjects (Japanese and 
Caucasian) can have their typical diet pri or to the study; all subjects (Japanese and Caucasian) will receive 
identical meals on Day 1 (up to 24 hours post dose) in all treatment periods to maintain control. Doses will be 
administered with a glass (240 mL) of room temperature water after at least a 10-hour overnight fasting, with 
water restricted 1 hour before and 1 hour after dosing. Food will be provided to subjects approximately 4 hours 
after study drug administration. Vomiting occurring within 4 hours after dosing will be recorded. There w ill be 
at least a 72 -hour washout between maribavir doses for the subjects of Japanese descent.
The total number of nights subjects will be expected to stay at the CRC is approximately 2 for the non -Hispanic, 
Caucasian subjects and approximately 8 for the subje cts of Japanese descent. The maximal total duration of 
study participation for a non -Hispanic, Caucasian subject is approximately 37 days and approximately 47 days 
for the subjects of Japanese descent, if the maximum screening period, treatment, washout, a nd follow -up visit 
durations are used. 
Treatment Period:
In Treatment Period 1, all study subjects (both Japanese and Caucasian) will receive maribavir as a 
single oral dose of 400 mg.
In Treatment Periods 2 and 3, all subjects of Japanese descent will re ceive maribavir as a single oral 
dose of either 200 mg or 800 mg, depending upon randomization assignment.
Shire CONFIDENTIAL Page 17
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Assessments
Serial blood samples for PK analysis will be collected in each treatment period for the determination of 
maribavir and  plasma concentrations at pre -dose and up to approximately 24 hours post dose. 
These blood samples will be collected according to the Schedules of Assessments ( Table 1, Table2, 
Table 3, Table4, Table5, and Table 6).
Safety and tolerability will be determined th rough assessment of treatment -emergent adverse events 
(TEAEs) from the first dose to the post -treatment follow -up telephone call at 7 (±4) days after the last 
dose of IP, and vital signs, electrocardiogram (ECG), and clinical laboratory evaluations on Day 1 
pre-dose and up to 24 hours post dose in each treatment period .
Follow -up
A post- treatment follow -up telephone call will occur at 7 (±4) days after the last dose of IP for each 
subject. Subjects who experience AEs will be follow ed longer if needed, incl uding an unscheduled 
clinic visit if appropriate, depending on the nature, severity, and seriousness of the AE.
Inclusion and exclusion criteria:
Inclusion Criteria:
1.An understanding, ability, and w illingness to fully comply with study procedures and restrictions. 
2.Ability to voluntarily provide written, signed, and dated (personally or via a legally -authorized 
representative) informed consent/assent as applicable to p articipate in the study.
3.Healthy subjects of Japanese descent must have been born in Japan and must not have lived outside of 
Japan for >10 years; both parents and all 4 grandparents must be of Japanese origin. Healthy, 
non-Hispanic, Caucasian subjects mus t have both parents and all 4 grandparents of non -Hispanic, 
Caucasian origin.
4.Age 18 years to 55 years, inclusive at the time of consent. The date of signature of the informed 
consent is defined as the beginning of the screening period. This inclusion crit erion will only be 
assessed at the first screening visit.
5.Male, or non -pregnant, non -breastfeeding female who agrees to comply with any applicable 
contraceptive requirements of the protocol or females of non -childbearing potential. 
6.Healthy as determined by the investigator on the basis of screening evaluations. Healthy status is 
defined by absence of evidence of any active or chronic disease following a detailed medical and 
surgical history, a complete physical examination including vital signs, 12 -lead EC G, hematology, 
blood chemistry (includes thyroid stimulating hormone [TSH] and free T4 at screening only), and 
urinalysis.
7.Hem oglobin for males 135.0 g/L and females 120.0 g/L at screening and on Day -1.
8.BMI betw een 18.5 and 28.0 kg/m2inclusive and a body weight >45 kg (99 lbs.). This inclusion 
criterion w ill only be assessed at the first screening visit.
9.Ability to swallow  a dose of IP.
Exclusion Criteria:
1.History of any hematological, hepatic, respiratory, cardiovascular, renal, neur ological, or psychiatric 
disease, gall bladder removal, or current recurrent disease that could affect the action, absorption, or 
disposition of the IP, or clinical or laboratory assessments.
2.Current or relevant history of physical or psychiatric illness, any medical disorder that may require 
treatment or make the subject unlikely to fully complete the study, or any condition that presents undue 
risk from the IP or procedures.
3.Known or suspected intolerance or hypersensitivity to maribavir, closely -related compounds, or any of 
the stated ingredients.
4.Significant illness, as judged by the investigator, within 2 weeks of the first dose of IP.
5.Donation of blood or blood products (eg, plasma or platelets) w ithin 60 days prior to receiving the first 
dose of IP.
6.Have taken another IP w ithin 30 days or five half -lives of that IP, whichever is greater, prior to the first 
dose of maribavir.
7.Have been enrolled in a clinical study (including vaccine studies) w ithin 30 days prior to the first dose 

Shire CONFIDENTIAL Page 18
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
of IP that, in the inv estigator’s opinion, may impact this study.
8.Have had any substantial changes in eating habits within 30 days prior to the first dose of IP, as 
assessed by the investigator.
9.Confirmed systolic blood pressure >139 mmHg or <89 mmHg, and diastolic blood pressu re 
>89mmHg or <49 mmHg.
10.Twelve-lead ECG demonstrating corrected QT interval (QTc) >450 msec at screening. If QTc exceeds 
450msec, the ECG should be repeated 2 more times and the average of the 3 QTc values should be 
used to determine the subject’s eligib ility. 
11.Known history of alcohol or other substance abuse, including synthetic cannabinoids within the last 
year.
12.Male subjects who consume more than 21 units of alcohol per week or 3 units per day. Female subjects 
who consume more than 14 units of alcohol per w eek or 2 units per day. (1 alcohol unit=1 beer or 
1wine [5 oz/150 mL] or 1 liquor [1.5 oz/40 mL] or 0.75 oz alcohol).
13.A positive urine test for drugs of abuse, alcohol, or cotinine at screening or on Day -1.
14.A positive human immunodeficiency virus (HIV), hepatitis B surface antibody (HBsAg), or hepatitis C 
virus (HCV) antibody screen.
15.Use of tobacco in any form (eg, smoking or chewing) or other nicotine -containing products in any form 
(eg, gum, patch). Ex -users must report that they have stopped usin g tobacco for at least 30 days prior to 
receiving the first dose of IP.
16.Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine 
withdrawal headaches. (1 caffeine unit is contained in the follow ing items: one 6 oz [1 80mL] cup of 
coffee, two 12 oz [360 mL] cans of cola, one 12 oz cup of black tea, and three 1 oz [85 g] chocolate 
bars. (Decaffeinated coffee, herbal tea, or cola are not considered to contain caffeine).
17.Prior screen failure, randomization, enrollment, or participation in this study.
18.Current use of any prescription medication (with the exception of hormonal replacement therapy) 
within 30 days of the first dose of IP. Current use of any over the counter medication (including herbal 
preparations like St. Joh n’s wort and ginkgo biloba, or homeopathic preparations) w ithin 14 days of the 
first dose of IP.
19.Ingestion of known cytochrome P450 (CYP)3A modulators within 7 days of Day 1, Period 1 (includes 
grapefruit or grapefruit juice, oranges, Seville oranges, veg etables from the mustard green family [eg, 
kale, broccoli, w atercress, collard greens, kohlrabi, Brussels sprouts, mustard], charbroiled meats, and 
products containing these ingredients).
20.History of active or chronic oral/nasal cavity infections, gastroesophageal reflux, asthma treatment with 
albuterol, zinc supplementation.
21.Subjects with dry mouth syndrome or burning mouth syndrome or menopausal women suffering from 
dysgeusia.
22.Subjects who have acute gastrointestinal symptoms at screening or admis sion (eg, nausea, vomiting, 
diarrhea, and heartburn).
Maximum duration of subject involvem ent in the study:
Planned duration of screening period: Subjects w ill be screened w ithin 28 days prior to the first dose of the 
IP.
Planned duration of treatment per iod: All subjects will be admitted to the CRC on Day - 1. Caucasian 
subjects will be administered a single oral dose of maribavir 400 mg on Day 1 and will be discharged on 
Day 2. They will spend a total of approximately 3 days and 2 nights at the CRC. Subje cts of Japanese 
descent will receive a single oral dose of 400 mg maribavir on Day 1 in Treatment Period 1, and w ill be 
dosed in a crossover fashion with a single dose of maribavir of either 200 mg or 800 mg based on their 
randomization assignment on Day 1 in Treatment Periods 2, and 3. They will spend in total approximately 
9days and 8 nights at the CRC.
Planned duration of washout period betw een single doses of maribavir for the subjects of Japanese descent: 
There will be a 72 -hour washout period from single dose to single dose of maribavir. This is not applicable 
for Caucasian subjects, as they will rece ive one single dose of maribavir. 
Planned duration of follow -up: There w ill be a post -treatment follow -up telephone call at 7 (±4) days after 
the last dose of IP for each subject. Subjects who experience AEs will be followed longer if needed, 
Shire CONFIDENTIAL Page 20
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
parameters will be presented as w ell. 
Figures ofindividual andmean (±SD) maribavir concentration -time profiles wi ll be generated on linear and 
semi -log scales. The mean plots will be generated and presented by overlaying the Japanese cohort and 
non-Hispanic, Caucasian cohort. Figures of PK parameters and dose -normalized C max, AUC last, and AUC 0-infvs. 
dose in Japanes e subjects will be generated. Box -Whisker plots for selected PK parameter will be generated 
with Japanese cohort and non -Hispanic Caucasian side by side. 
In order to compare the PKs of maribavir betw een subjects of Japanese descent and matched, non -Hispan ic, 
Caucasian subjects, the differences of log -transformed PK parameters (AUC last, AUC 0-inf, and C max) from the 
maribavir 400 mg oral dose will be examined between cohorts using an analysis of variance model. The 
geometric mean ratio and its 90% CI of PK p arameters will be provided from the model. In addition, the 
difference of log -transformed dose -norm alized AUC 0-inf, AUC lastand C maxwill be examined betw een the 
Japanese cohort estimated at the 200 mg dose and the non -Hispanic, Caucasian cohort estimated at the 400 mg 
dose, as w ell as between the Japanese cohort estimated at the 800 mg dose and the non -Hispanic, Caucasian 
cohort estim ated at 400 mg dose, using an analysis of variance model. The geometric mean ratio and its 90% CI
of PK parameters will be provided from the model. Forest plots of geometric mean ratios for selected PK 
parameters between Japanese cohort and the non -Hispani c Caucasian cohort at 400 mg will be generated.  
Dose proportionality will also be examined for maribavir PK parameters for the Japanese subjects. Dose 
proportionality will be assessed f or C maxand AUC (AUC lastand AUC 0-inf) using the power model. The pow er 
model assumes a linear relationship betw een the natural log transformed PKparameter and the natural log 
transformed dose.
ln (Parameter) = α + β × ln (Dose) + Random error
Where α is the intercept, β is the slope, and Random error is a random residual error. Dose proportionality will 
be assessed by estimating mean slope with the corresponding two -sided 90% CI from the pow er model. The fold 
increase in PK parameters and associated 90% C I when doubling the dose will be presented.  
Safety Endpoints:
Safety will be assessed for the following evaluations:
Number, severity, seriousness, and causality of TEAEs
Changes in vital signs , ECGs, and clinical laboratory results (hematology, chemistry, and urinalysis) 
from baseline to post -baseline time points. Baseline is defined as the last non -missing assessment prior 
to the first dose.
Statistical Methodology for Safety Endpoints:
Safety data, including TEAEs, laboratory tests, ECGs, and vital signs, will be summarized. Quantitative safety 
data, as w ell as the difference from baseline, if applicable, will be summarized by descriptive statistics. 
Frequency counts will be compiled for classification of qualitative safety data. Direct safety comparisons 
betw een the two cohorts will be presented from the maribavir 400 mg dosing data. All other safety data from the 
200 mg and 800 mg doses in the subjects of Japanese descent w ill be summar ized and listed. 
Sample Size Justification:
The sample size consideration for the primary objective of evaluating the PK profile of maribavir, administered 
as a single oral dose at 400 mg, betw
een Japanese subjects and matched, healthy, adult, non -Hispani c, 
Caucasian subjects is based on feasibility and comparable studies. A total of 24 subjects (12 subjects of 
Japanese descent and 12 matched, non -Hispanic, Caucasian subjects) will be targeted to be enrolled in the study.

Shire CONFIDENTIAL Page 21
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Table 1 Schedule of Assessments for Subjects of Japanese Descent
Visit ScreeningPre-dose 
AssessmentsTreatm ent 
Period 1Washout 
PeriodiTreatm ent 
Period 2Washout 
PeriodiTreatm ent 
Period 3Early 
TerminationFollow -upj
Study Day –28 to -02 -1 1 2 3-5 1 2 3-5 1 2 7 (±4)
Informed consent X
Inclusion/exclusion 
criteriaX X
Dem ographyaX
Medical/medication 
historyX X
Physical examination X XbX X X X X X X
Vital signs (BP, pulse, 
temperature, and 
respiratory rate)cX X X X X X X X X
Height and weightdX X X X X X X
Electrocardiogram 
(12-lead)X X X X X X X X X
Biochemistry, 
hematology, and 
urinalysisX X X X X X X X X
HIV, HBsAg, and 
HCV antibodiesX
Serum β -HCG 
pregnancy test 
(females only)eX X
Urine pregnancy test 
(females only)e X X X X
Urine drug, alcohol, 
and cotinine screeningf X X
IP administrationgX X X
PK blood samplinghX X X X X X
Check -in to the CRC X
Discharge from the 
CRCX
Shire CONFIDENTIAL Page 22
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Table 1 Schedule of Assessments for Subjects of Japanese Descent
Visit ScreeningPre-dose 
AssessmentsTreatm ent 
Period 1Washout 
PeriodiTreatm ent 
Period 2Washout 
PeriodiTreatm ent 
Period 3Early 
TerminationFollow -upj
Study Day –28 to -02 -1 1 2 3-5 1 2 3-5 1 2 7 (±4)
Adverse 
events/serious adverse 
eventsiX X X X X X X X X X
Concomitant 
medicationsX X X X X X X X X X
β-hCG=β -human chorionic gonadotropin; BP=blood pressure; CRC=clinical research center; HBsAg=hepatitis B surface antigen; HCV=hepatit is C virus; 
HIV=human immunodeficiency virus; IP=investigational product; PK=pharmacokinetic
a Subjects must have been born in Japan and must not have lived outside of Japan for >10 years; both parents and all 4 grandp arents of must be of Japanese 
origin. 
b If more than 2 days have passed since screening, a physical examination should be repeated on Day - 1.
c Vital signs will be obtained while subject is in the supine position on study days noted. BP at screening visit is compared on both arms. The same (right or left) 
arm with the higher blood pressure w ill be used throughout the study. Temperatu re will be taken at screening, at predose on Day 1, and on each study day.
d Height will be recorded at the screening visit only.
e Serum β -hCG testing is required at screening and on Day -1 for all female subjects. 
f Tests for drugs of abuse, alcohol, an d cotinine will be performed at screening and on Day -1. Testing for alcohol on Day -1 will be performed using an on -site 
breathalyzer test. 
g All maribavir doses will be administered with a glass (240 mL) of room temperature water after a 10 hour overnig ht fasting, with water restricted 1 hour before 
and 1 hour after dosing. All subjects (Japanese and Caucasian) can have their typical diet prior to the study; all subjects ( Japanese and Caucasian) will receive 
identical meals on Day 1 (up to 24 hours post dose) in all treatment periods to maintain control. Food will be provided to subjects approximately 4 hours after IP 
administration. Vomiting occurring within 4 hours after dosing will be recorded.
h PK samples will be collected pre- dose, 0.25, 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 16, 20, and 24 hours post dosing with the IP on Day 1 of all 3 treatment periods.
i Washout period of a minimum of 72 hours and a maximum of 73 hours after administration of the IP on Day 1. Following the washout period, subjects will be 
asked regarding concomitant medications and any AEs.
jThere will be a post -treatment follow -up telephone call at 7 (±4) days after the last dose of IP. Subjects who experience AEs will be followed longer if needed, 
including an unscheduled clinic v isit if appropriate, depending on the nature, severity, and seriousness of the AE.
Shire CONFIDENTIAL Page 23
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Table 2 Detailed Schedule of Assessments for Subjects of Japanese Descent for Days 1 and 2 of Treatment Period 1
Study Day Day 1aDay 2
Hour (relative to dosing time) Predose 0 0.25 0.5 1 1.5 2 3 4 5 6 8 12 16 20 24
Physical examinationbXe
Vital signs (BP, pulse, temperature, and 
respiratory rate)b,c XeX X
WeightbXe
Electrocardiogram (12 -lead)b,dXeX X
Biochemistry, hematology, and urinalysisbXeX
IP administrationfX
PK blood samplinggXeX X X X X X X X X X X X X X
Adverse events/serious adverse eventsbXeX X X
Concomitant medicationbXeX X
ECG=electrocardiogram; IP=Investigational Product; PK=pharmacokinetic; QTc=corrected QT interval
a There w ill be a minimum of 72 hours and a maximum of 73 hours washout period betw een adm inistration of the last dose of investigational product in 
Treatment Period 1 and Treatment Period 2. There w ill also be a minimum of 72 hours and a maximum of 73 hours washout period bet ween administration of the 
last dose of investigational product in Treatment Period 2 and Treatment Period 3. Follow ing washout, su bjects w ill be asked regarding concomitant medications 
and any AEs.
b In the event a subject is prematurely discontinued from the study or withdraws, every attempt should be made to complete thes e assessments.
c Vital signs will be obtained while subject i s in the supine position on study days noted. BP at screening visit is compared on both arms. The same (right or left) 
arm with the higher blood pressure w ill be used throughout the study. Temperature will be taken at screening, at predose on D ay 1, and on each study day.
dIf QTc exceeds 450 msec, the ECG should be repeated 2 more times and the average of the 3 QTc values should be used to determine the subject’s e ligibility. 
The subject must be resting in the supine position for at least 5 minutes prior t o collecting the ECG.
eBlood sampling assessments should be performed within 30 minutes prior to dose administration.  All other predose assessments should be completed w ithin 60
minutes of dose administration, with the exception of the physical examinatio n which should be completed within 90 minutes of dose administration. 
fAll maribavir doses will be administered with a glass (240 mL) of room temperature w ater after a 10 hour overnight fasting, w ithwater restricted 1 hour before 
and 1 hour after dosing . All subjects (Japanese and Caucasian) can have their typical diet prior to the study; all subjects (Japanese and Caucasian) will receive 
identical meals on Day 1 (up to 24 hours post dose) in all treatment periods to maintain control. Food will be provid ed to subjects approximately 4 hours after IP 
administration. Vomiting occurring within 4 hours after dosing will be recorded.
g The sponsor's expectation is that the investigator will ensure that every effort is made to collect all PK blood samples at t heprecise protocol scheduled time. PK 
blood collection must not deviate from the nominal collection time set forth in the protocol by more than 5 minutes from samples drawn within 4 hours post -
dose or by more than 15 minutes for samples drawn beyond 4 hou rs post -dose. Samples draw n outside these parameters will be considered a protocol deviation.
Shire CONFIDENTIAL Page 24
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Table 3 Detailed Schedule of Assessments for Subjects of Japanese Descent for Days 1 and 2 of Treatment Period 2
Study Day Day 1aDay 2
Hour (relative to dosing time) Predose 0 0.25 0.5 1 1.5 2 3 4 5 6 8 12 16 20 24
Physical examinationbXf
RandomizationcXf
Vital signs (BP, pulse, temperature, and 
respiratory rate)b,d XfX X
WeightbXf
Electrocardiogram (12 -lead)b,eXfX X
Biochemistry, hematology, and urinalysisbXfX
IP administrationgX
PK blood samplinghXfX X X X X X X X X X X X X X
Adverse events/serious adverse eventsbXfX X X
Concomitant medicationbXfX X
ECG=electrocardiogram; IP=Investigational Product; PK=pharmacokinetic; QTc=corrected QT interval
aThere will be a minimum of 72 hours and a maximum of 73 hours washout period between administration of the last dose of inves tigational product in Treatment Period 1 and 
Treatment Period 2. There will also be a minimum of 72 hours and a maximum of 73 hour s washout period between administration of the last dose of investigational product in 
Treatment Period 2 and Treatment Period 3. Following washout, subjects will be asked regarding concomitant medications and an y AEs.
bIn the event a subject is premature ly discontinued from the study or withdraws, every attempt should be made to complete these assessments.
cRandomization will occur in Treatment Period 2, Day -1 or Day 1.
dVital signs will be obtained while subject is in the supine position on study days noted. BP at screening visit is compared on both arms. The same (right or left) arm with the 
higher blood pressure will be used throughout the study. Temperature will be taken at screening, at predose on Day 1, and on each study day.
eIf QTc exceeds 450 msec, the ECG should be repeated 2 more times and the average of the 3 QTc values should be used to determine the subject’s e ligibility. The subject must be 
resting in the supine position for at least 5 minutes prior to collecting the E CG.
fBlood sampling assessments should be performed within 30 minutes prior to dose administration.  All other predose assessments should be completed w ithin 
60minutes of dose administration, with the exception of the physical examination which should be completed w ithin 90 minutes of dose administration. 
gAll maribavir doses will be administered with a glass (240 mL) of room temperature water after a 10 hour overnight fasting, with water restricted 1 hour before and 1 hour after 
dosing. All subjects (J apanese and Caucasian) can have their typical diet prior to the study; all subjects (Japanese and Caucasian) will receive ide ntical meals on Day 1 (up to 
24hours post dose) in all treatment periods to maintain control. Food will be provided to subjects ap proximately 4 hours after IP administrati on. Vomiting occurring within 4 hours 
after dosing will be recorded.
hThe sponsor's expectation is that the investigator will ensure that every effort is made to collect all PK blood samples at t he precise protocol scheduled time. PK blood collection 
must not deviate from the nominal collection time set forth in the protocol by more than 5 minutes from samples drawn within 4 hours post- dose or by more than 15 minutes for 
samples drawn beyond 4 hours post-dose. Sam ples drawn outside these parameters will be considered a protocol deviation.
Shire CONFIDENTIAL Page 25
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Table 4 Detailed Schedule of Assessments for Subjects of Japanese Descent for Days 1 and 2 of Treatment Period 3
Study Day Day 1aDay 2
Hour (relative to dosing time) Predose 0 0.25 0.5 1 1.5 2 3 4 5 6 8 12 16 20 24
Physical examinationbXe
Vital signs (BP, pulse, temperature, and 
respiratory rate)b,c XeX X
WeightbXeX
Electrocardiogram (12 -lead)b,dXeX X
Biochemistry, hematology, and urinalysisbXeX
IP administrationfX
PK blood samplinggXeX X X X X X X X X X X X X X
Adverse events/serious adverse eventsbXeX X X
Concomitant medicationbXeX X
ECG=electrocardiogram; IP=Investigational Product; PK=pharmacokinetic; QTc=corrected QT interval
a There w ill be a minimum of 72 hours and a maximum of 73 hours washout period betw een adm inistration of the last dose of investigational product in 
Treatment Period 1 and Treatment Period 2. There w ill also be a minimum of 72 hours and a maximum of 73 hours washout period betw een administration of the 
last dose of investigati onal product in Treatment Period 2 and Treatment Period 3. Follow ing washout, subjects w ill be asked regarding concomitant medications 
and any AEs.
b In the event a subject is prematurely discontinued from the study or withdraws, every attempt should be ma de to complete these assessments.
c Vital signs will be obtained while subject is in the supine position on study days noted. BP at screening visit is compared o n both arms. The same (right or left) 
arm with the higher blood pressure w ill be used throughou t the study. Temperature will be taken at screening, at predose on Day 1, and on each study day.
dIf QTc exceeds 450 msec, the ECG should be repeated 2 more times and the average of the 3 QTc values should be used to determine the subject’s e ligibility. 
The subject must be resting in the supine position for at least 5 minutes prior to collecting the ECG.
eBlood sampling assessments should be performed within 30 minutes prior to dose administration.  All other predose assessment s should be completed w ithin
60minutes of dose administration, with the exception of the physical examination which should be completed w ithin 90 minutes of dose administration.
fAll maribavir doses will be administered with a glass (240 mL) of room temperature w ater after a 10 ho ur overnight fasting, with water restricted 1 hour before 
and 1 hour after dosing. All subjects (Japanese and Caucasian) can have their typical diet prior to the study; all subjects ( Japanese and Caucasian) will receive 
identical meals on Day 1 (up to 24 h ours post dose) in all treatment periods to maintain control. Food will be provided to subjects approximately 4 hours after I P 
administration. Vomiting occurring within 4
hours after dosing will be recorded.
g The sponsor's expectation is that the investig ator will ensure that every effort is made to collect all PK blood samples at the precise protocol scheduled time. PK 
blood collection must not deviate from the nominal collection time set forth in the protocol by more than 5 minutes from samples drawn wi thin 4 hours post -
dose or by more than 15 minutes for samples drawn beyond 4 hours post -dose. Samples draw n outside these parameters will be considered a protocol deviation.
Shire CONFIDENTIAL Page 26
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Table 5 Schedule of Assessments for Non -Hispanic, Caucasian Subjects
Visit Screening Predose Assessments Treatm ent Period 1 Early Termination Follow -upi
Study Day –28 to -02 -1 1 2 7 (±4)
Informed consent X
Inclusion/exclusion criteria X X
Dem ographyaX
Medical/medication history X X
Physical examination X XbX X X
Vital signs (BP, pulse, temperature, and respiratory rate)cX X X X X
Height and weightdX X X X X
Electrocardiogram (12 -lead) X X X X X
Biochemistry, hematology, and urinalysis X X X X X
HIV, HBsAg, and HCV antibodies X
Serum β -HCG pregnancy test (females only)eX X
Urine pregnancy test (females only)eX X
Urine drug, alcohol, and cotinine screeningfX X
IP administrationgX
PK blood samplinghX X
Check -in to the CRC X
Discharge from the CRC X
Adverse events/serious adverse eventsiX X X X X X
Concomitant medication X X X X X X
β-hCG=β -hum an chorionic gonadotropin; BP=blood pressure; CRC=clinical research center; HBsAg=hepatitis B surface antigen; HCV=hepatit is Cvirus; HIV=human 
immunodeficiency virus; IP=investigatio nal product; PK=pharmacokinetic
aSubjects must have both parents and all 4 grandparents of non -Hispanic, Caucasian descent. 
b If more than 2 days have passed since screening, a physical examination should be repeated on Day -1.
cVital signs will be obtained while subject is in the supine position on study days noted. BP at screening visit is compared o n both arms. The same (right or left) arm with the 
higher blood pressure will be used throughout t he study. Temperature will be taken at screening, at predose on Day 1, and on each study day.
d Height will be recorded at the screening visit only.
e Serum β -hCG testing is required at screening and on Day -1 for all female subjects. Urine pregnancy tests will be performed prior to dosing on Day 1 for all female subjects. 
f Tests for drugs of abuse, alcohol, and cotinine will be performed at screening and on Day -1. Testing for alcohol on Day -1 will be performed using an on -site breathalyzer test.
g All maribavir doses will be administered with a glass (240 mL) of room temperature water after a 10 hour overnight fasting, w ith water restricted 1 hour before and 1 hour after 
dosing. Food will be provided to subjects approximat ely 4 hours after IP administration. Vomiting occurring within 4 hours after dosing will be recorded. 
hCollection time points for PK sampling will include pre -dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 20, and 24 hours post dosing with the IP on Day 1.
iThere will be a post -treatment follow -up telephone call at 7 (±4) days after the last dose of IP. Subjects who experience AEs will be followed longer if needed, in cluding an 
unscheduled clinic visit if appropriate, depending on the nature, severit y, and seriousness of the AE.
Shire CONFIDENTIAL Page 27
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Table 6 Detailed Schedule of Assessments for Non -Hispanic Caucasian Subjects for Days 1 and 2 of Treatment Period 1
Study Day Day 1 Day 2
Hour (relative to dosing 
time)Predose 0 0.25 0.5 1 1.5 2 3 4 5 6 8 12 16 20 24
Physical examinationaXd
Vital signs (BP, pulse, 
temperature, and respiratory 
rate)a,bXdX X
WeightaXdX
Electrocardiogram (12 -lead)a,cXdX X
Biochemistry, hematology, 
and urinalysisa XdX
IP administrationeX
PK blood samplingfXdX X X X X X X X X X X X X X
Adverse events/serious 
adverse eventsa XdX X X
Concomitant medicationaXdX X
ECG=electrocardiogram; IP=Investigational Product; PK=pharmacokinetic; QTc=corrected QT interval
aIn the event a subject is prematurely discontinued from the study or w ithdraws, every attempt should be made to complete thes e assessments.
bVital signs will be obtained while sub ject is in the supine position on study days noted. BP at screening visit is compared on both arms. The same (right or left) 
arm with the higher blood pressure w ill be used throughout the study. Temperature will be taken at screening, at predose on D ay 1, and on each study day.
cIf QTc exceeds 450 msec, the ECG should be repeated 2 more times and the average of the 3 QTc values should be used to determine the subject’s e ligibility. 
The subject must be resting in the supine position for at least 5 minutes p rior to collecting the ECG.   
dBlood sampling assessments should be performed w ithin 30 minutes prior to dose administration.  All other predose assessments should be completed within 
60 minutes of dose administration, with the exception of the physical e xamination which should be completed w ithin 90 minutes of dose administration.
eAll maribavir doses w ill be administered with a glass (240 mL) of room temperature w ater after a 10 hour overnight fasting, w ith water restricted 1 hour before 
and 1 hour afte r dosing. Food will be provided to subjects approximately 4 hours after IP administration. Vomiting occurring within 4 hours after dosing will be 
recorded.
f The sponsor's expectation is that the investigator will ensure that every effort is made to collec t all PK blood samples at the precise protocol scheduled time. PK 
blood collection must not deviate from the nominal collection time set forth in the protocol by more than 5 minutes from samples drawn within 4 hours post -
dose or by more than 15 minutes f or samples drawn beyond 4 hours post -dose. Samples draw n outside these parameters will be considered a protocol deviation.
Shire CONFIDENTIAL Page 28
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
1. BACKGROUND INFORMATI ON
1.1 Indication and Current Treatment Options 
Cytomegalovirus (CMV) is a beta herpesvirus that commonly  infects humans; serologic 
evidence of prior infection can be found in 40% to 100% of various adult populations (de la Hoz 
et al. 2002). However, s ymptomatic CMV infection or CMV disease occurs almost exclusively  
in individuals with compromised immune sy stems. CM V remains a significant problem for 
patients undergoing various ty pes of transplants that are associated with the use of potent 
immunosuppressive chemotherap y, including hematopoietic stem cell transplants (HSCT) and 
solid organ transplants (SOT) ( de la Hoz et al. 2002
; Razonable and Emery  2004 ).
It has been found that CMV infection increases incidence of opportunistic infections and graft 
rejection, and decreased allograft and patient survival ( Rubin 1989; Hodson et al. 2005; 
Ljungman et al. 2006 ). Organ- specific associations with CMV infection include bronchiolitis 
obliterans in lung recipients, vanishing bile duct sy ndrome in liver recipients, accelerated 
transplant vasculopath y in heart recipients and transplant glomerulopath y, transplant renal artery 
stenosis or increased risk of transplant rejection ( Razonable and Emery  2004 ; Legendre and 
Pascual 2008; Richardson et al. 1981 ; Pouria et al. 1998; Farrugia and Schwab 1992). These 
effects are believed to be mediated b y the ability of the virus to modulate the immune system, 
either directly  or secondary  to the host antiviral response through regulation of cy tokine, 
chemokine, and/or growth factor production.
CMV prevention strategies (proph ylaxis) for various high- risk transplant subjects exist, however, 
CMV infection or disease can still occur within the ear ly (initial ~3 months) or later 
post-transplantation time periods ( Boeckh et al. 2003 ; Legendre and Pascual 2008). I n kidney  
transplant recipients, the highest incidence of s ymptomatic CMV infection (sy ndrome) or disease 
occurs in CMV -seronegative recipients who receive a kidney  from a CMV -seropositive donor 
(D+/R -) (Paya et al. 1989 ; Kanj et al. 1996 ; Singh et al. 2004 ; Winston et al. 1 995).
Although the currentl y availabl e systemic anti- CMV agents, intravenous (IV) or oral ganciclovir, 
oral valganciclovir (a prodrug of ganciclovir with improved bioavailability ), IV foscarnet, and IV 
cidofovir are generall y effective, their use is limited by their respective toxicities; bon e marrow 
suppression caused b y ganciclovir/valganciclovir and renal impairment caused by foscarnet or 
cidofovir ( Boeckh et al. 2003 ; Ljungman et al. 2001
; Reusser et al. 2002 ; Salzberger et al. 1997). 
These toxicities are of particular concern in transplant patients, in whom the bone marrow has 
been ablated or significantly  suppressed (HSCT patients), who receive ongoing 
immunosuppressants to prevent organ rejection (SOT patients) or graft
-versus host disease (in 
HSCT patients), or who may require the use of other therapies that are potentially  toxic to the 
kidney s or other organs (SOT and HSCT patients). 
Development of anti -viral resistance to currently  available anti- CMV agents is also an ongoing 
clinical problem in solid organ and stem cell transplantation leading to graft loss and even 
mortality  for some transplant patients. As described by  Limay e et al. 2000, ganciclovir resistance 
developed in 7% D+/R -kidney , liver, and pancreas recipients who were prophy laxed with 
3 months of oral ganciclovir. Ganciclovir resistant disease accounted for 20% of CMV dis ease, 
Shire CONFIDENTIAL Page 29
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
occurred late (a median of 10 months after transplantation), was associated with higher intensit y 
of immunosuppression, and was considered a clinically serious concern ( Avery  2007)
.
There are no approved therapies for the treatment of CMV infection or CMV disease in 
transplant recipients, and no approved treatment for CMV infection or disease that is resistant or 
refractory  to currentl y available therapies in an y population. Maribavir is currentl y in Phase 3 
clinical d evelopment for the treatment of CMV infection or disease, including those resistant or 
refractory  to ganciclovir, valganciclovir, foscarnet, or cidofovir, in transplant recipients. 
1.2 Product Background
1.2.1 Preclinical Information
Refer to the latest version of the maribavir (SHP620/TAK -620) Investigator’s brochure (IB).
1.2.2 Clinical Information
Maribavir is a potent and selective, orally  bioavailable antiviral drug with a novel mechanism of 
action against CMV ( Chulay  et al. 1999 ) and a favorable nonclinical and clinical safet y profile. It 
is a potent member of a new class of drugs, the benzimidazole ribosides ( Williams et al. 2003 ). 
In side -by-side in vitro assay s maribavir is 3 -fold to 20 -fold more potent than ganciclovir and 
cidofovir, and at least 100 -fold more potent than foscarnet ( Biron et al. 2002; Drew et al. 2006 ). 
Maribavir is active in vitro against strains of CMV that are resistant to ganciclovir, foscarnet, or 
cidofovir.
Unlike currently available anti -CMV agents that inhibit CMV deoxy ribonucleic acid (DNA) 
polymerase, maribavir inhibits the CMV UL 97 serine/threonine kinase b y competitively  
inhibiting the binding of adenosine triphosphate (ATP) to the kinase ATP -binding site ( Biron et 
al. 2002 ; Williams et al. 2003 ; Krosky  et al. 2003 ; Wolf et al. 2001
; Kern et al. 2004); the 
dominant phenoty pic inhibitory  effect of maribavir is on viral DNA assembly  and egress of vira l 
capsids from the nucleus of infected cells ( Biron et al. 2002 ). Except for ganciclovir, maribavir 
does not antagonize the effects of other anti -viral (anti- CMV) agents. Since ganciclovir is 
dependent on its initial phosphory lation by  the viral UL97 kinase , maribavir may  antagonize its 
clinical efficacy . 
1.2.3 Pharmacokinetics and metabolism
Results from the Phase 1 studies demonstrated that following oral administration of the adult 
tablet formulation, maribavir was rapidly and well absorbed with mean peak plas ma 
concentrations generally  achieved between 1 and 3 hours post dose. After administration of 
single and multiple doses (both twice dail y [BID] and 3 times daily [TID] regimens) over 
28days, total maribavir plasma concentrations increased with increasing dose proportionally  up 
to 900 mg. At dose levels ≥900 mg BID, there was no apparent increase in maximum observed 
plasma concentration (C max) levels, and above this level, the increase in area under the plasma 
concentration versus time curve (AUC) may  be le ss than dose proportional. Maribavir 
demonstrates time-independent pharmacokinetics (PK). Pharmacokinetics data obtained in 
Phase 2 studies were similar to the data observed in healthy  volunteers.
Shire CONFIDENTIAL Page 30
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Administration of maribavir in conjunction with food resulted in a 28% decrease in C maxwithout 
a significant effect on AUC when compared to administration under fasting conditions. 
Bioavailability  of a 100 mg tablet was unaffected by  crushing the tablet or changes in gastric pH.
Maribavir was bound to plasma proteins, namel y human serum albumin, lipoproteins, and 
alpha -1-acid-glycoprotein. The fraction of unbound maribavir was estimated at approximately  
1.5% in healthy  subjects and 0.96% in transplant patients. The apparent plasma elimination 
half-life for unchanged maribavir was approximately  5-7 hours. Maribavir is metabolized 
primarily  in the liver through cy tochrome P450 (CYP)3A4 pathway  with the formation of the 
primary  metabolite, VP44469. VP44469 does not have anti
-CMV activity  and does not affect 
major CYP enzy mes or transporter activity . Renal clearance is a minor route of elimination of 
maribavir. Data from a Phase 1 study  demonstrated no gender differences in maribavir PK. A 
population PK analy sis conducted using pooled PK data from HP620- 202 and SHP620-
203 did 
not show apparent PK differences in Asian vs. non -Asian subjects; however, the sample size of 
Asian subjects was small (n=7).
Clinical studies conducted to evaluate the potential of drug -drug interactions demonstrated the 
following:
Concomitant admi nistration of maribavir (400 mg BID) with tacrolimus, a substrate of 
CYP3A4 and P -glycoprotein (P -gp), resulted in increased tacrolimus C maxand AUC by  
38% and 51%, respectively .
Maribavir does not have a clinically  significant effect on the activity  of CY P1A2, 
CYP3A, CYP2C9, or CYP2D6; however, it inhibits CYP2C19 activity  (based on 
plasma omeprazole/5 -OH omeprazole ratio). A follow -up clinical study  indicates 
maribavir had no effect on the PK of voriconazole (a CYP2C19 substrate).
In vivo, maribavir 400 mg BID did not affect digoxin AUC; however, it increased C max
by 24.8%.
Concurrent administration of rifampin, an inducer of CYP3A4 and P -gp, and maribavir 
significantl y reduced plasma concentrations of maribavir, resulting in a 61% reduction 
in AUC, reduce d half -life, and significantl y increased clearance, most likely  due to 
induction of hepatic and intestinal CYP3A4, and possible enhancement of P -gp 
transport.
Concomitant administration of antacid has no effect on maribavir exposure.
Concomitant administration of ketoconazole increased maribavir AUC and C maxby 
46% and 10%, respectively .
1.2.4 Efficacy
Two Phase 2 studies were conducted to assess the safet y, tolerability, and anti -CMV activity  of 
maribavir for treatment of CMV infections: Study  1262 -202 (SHP620 -202) in transplant subjects 
with CMV infections or disease that are resistant or refractory to treatment with anti -CMV 
agents conducted in the US and Study  1262- 203 (SHP620- 203) in transplant recipients with 
wild-type CMV infections who do not hav e CMV organ disease (as ymptomatic) conducted in 
Europe. In both these studies subjects received maribavir at 1 of 3 do se strengths, 400, 800, or 
1200 mg BID, and both studies demonstrated favorable anti -CMV activity  for maribavir, besides 
showing that mari bavir was well tolerated with no safet y concerns at all doses evaluated.
Shire CONFIDENTIAL Page 31
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Phase 3 registration trials are underway  based on the results from these Phase 2 studies for CMV 
treatment.
1.2.5 Safety
Maribavir has been administered across a broad range of oral doses f rom 50 mg/day  to 
2400 mg/day . Clinical safety  experience has been obtained from 16 Phase 1 studies in adult, 
healthy  volunteers, special populations (subjects with renal and hepatic impairment, and stable 
renal transplant recipients), and human immunodefic iency  virus (HIV)-infected subjects. These 
studies included adult subjects only . Maribavir has been administered across a broad range of 
oral doses from 50 mg/day to 2400 mg/day . The most common TEAE in single -and multiple -
dose Phase 1 studies was taste d isturbance (d ysgeusia). A definitive corrected QT interval (QTc) 
study  demonstrated no clinically  significant repolarization effect of maribavir administered 
orally  at single doses of 100 mg and 1200 mg in healthy  subjects. In addition, no other 
significant electrocardiographic effects of maribavir were found.
Maribavir was safe and well tolerated in Phase 1 studies. The most common treatment -emergent 
adverse event (TEAE) in single -and multiple -
dose Phase 1 studies was taste disturbance 
(dysgeusia). Among maribavir -treated subjects, d ysgeusia was reported b y up to 80% of subjects 
across the single -dose studies (dose range, 50 mg to 600 mg) and b y 64% to 92% of subjects 
across the multiple-dose studies (dose range, 300 mg/day  to 2400 mg/day). Of the 259 case s of 
dysgeusia reported by  maribavir -treated subjects in Phase 1, 252 were mild or moderate and 
7were of severe intensity. Dy sgeusia was generally  reported as a bitter or metallic taste that was 
considered related to maribavir administration. I n a few cases, the taste disturbance was reported 
as more noticeable with liquids, especially  cold beverages. Dy sgeusia usually  started within 
1hour after maribavir dosing and resolved within approximately  8 hours after dosing in the 
single -dose studies (range, 0.5 hours to 25 hours) and within 1 day after the last dose in the 
multiple -dose studies. No subjects were withdrawn from treatment because of taste disturbance. 
Among maribavir -treated subjects, 94% (778/831) of TEAEs were of mild or moderate intensit y; 
62% ( 517/831) of TEAEs were considered b y the investigator to be related to maribavir. 
Maribavir had a favorable safet y and tolerability  profile in both the Phase 2 and Phase 3 trials for 
CMV prophy laxis. The most common TEAEs that appeared to be associated with maribavir 
treatment were d ysgeusia and gastrointestinal (GI) -related events (eg, diarrhea, nausea, and 
vomiting). These events were generally  of mild or moderate intensit y. There were no signals of 
clinically  significant effects of maribavir on vital si gns, electrocardiogram (ECG) parameters, or 
laboratory  findings in the studies conducted for CMV prophy laxis.
In both Phase 2 studies for treatment of CMV infection (Studies SHP620 -202 and SHP620 -203), 
subjects received maribavir at 1 of 3 dose strengths: 400, 800, or 1200 mg BID, and both studies 
demonstrated that maribavir was well -tolerated with no safet y concerns at all doses evaluated. In 
Study SHP620 -202, TEAEs that occurred were events already  observed in previous studies (ie, 
dysgeusia, GI events, e levated immunosuppressant drug levels, and rash) and there were no 
additional safet y concerns raised from this study. In Study  SHP620- 203, TEAEs that occurred at 
a higher frequency  in maribavir subjects compared with valganciclovir were events alread y 
observed in previous studies with maribavir (ie, dy sgeusia, GI events, and elevated 
immunosuppressant drug levels). Anal yses of clinical laboratory , vital signs, and ECG data did 
not identify  any clinically meaningful differences across the maribavir treatment cohorts .
Shire CONFIDENTIAL Page 32
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
To date, maribavir has shown an overall favorable safet y profile in placebo -controlled studies, 
open -label studies, and in studies that compared maribavir with other CMV therapies 
(ganciclovir, valganciclovir) for proph ylaxis and for CMV treatment in HSCT and SOT patients.
Refer to the latest version of the maribavir IB for the most detailed and most current information 
regarding the drug metabolism, PK, efficacy  and safet y of maribavir.
1.3 Risk/Benefit and Ethical Assessment
To date, maribav ir has been safe and well tolerated in placebo -controlled studies, open -label 
studies, and in studies that compared maribavir with other CMV therapies (ganciclovir, 
valganciclovir) for prophylaxis and for CMV treatment in stem cell transplant and SOT patie nts. 
Treatment effect on viral load reduction (confirmed undetectable plasma CMV DNA: 67% of 
subjects within 6 weeks in Study  SHP620- 202; 60.5% of subjects in 3 weeks and 77.3% of 
subjects in 6 weeks in Study  SHP620- 203) seen in Phase 2 treatment studies c oupled with 
acceptable safet y and tolerability establish the positive benefit -risk profile and warrant 
continuation of maribavir development in the Phase 3 treatment studies.
Alway s refer to the latest version of the maribavir IB for the overall benefit/ri sk assessment and 
the most accurate and current information regarding drug metabolism, PK, efficacy , and safet y of 
maribavir. 
1.4 Compliance Statement
This study  will be conducted in accordance with this protocol, the I nternational Council for 
Harmonisation G uideline for Good Clinical Practice E6 (ICH GCP, 1996; E6 R2, 2017), Title 21 
of the US Code of Federal Regulations (US CFR), the European Union (EU) Directives 
(2001/20/EC; 2005/28/EC), and applicable national and local regulatory  requirements.
The respon sibilities of the study  sponsor and investigator(s) are described fully  in Appendix 1
.
Shire CONFIDENTIAL Page 34
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
3. STUDY DESIGN
3.1 Study Design and Flow Chart
This is a Phase 1, open-label, randomized, crossover, partiall y fixed sequence, si ngle-center 
study  to evaluate the PK profile, safety , and tolerability  of maribavir administered in healthy , 
adult subjects of Japanese descent and matched, healthy, adult, non -Hispanic, Caucasian 
subjects. A total of 24 subjects will be enrolled: 12 subje cts of Japanese descent and 
12 non-Hispanic, Caucasian subjects. Non-
Hispanic, Caucasian subjects will be matched to 
Japanese subjects based on age ( years), sex, and body  mass index (BMI) ( 15%).
The study  design flow chart is presented in Figure 1.
Subjects will be screened within 28 day s prior to the first dose of the investigational product (IP). 
Subjects will be admitted to the Clinical Research Center (CRC) on Day  -1. 
For the non -Hispanic, Caucasian group, the stud y will comprise a 28 -day Screening Period and 
Treatment Period 1. These subjects will receive a single oral dose of 400 mg maribavir on Day 1 
and will be discharged on Day  2. For this cohort there will be one treatment period ( Table 5and 
Table 6).
For the subjects of Japanese descent, the study  will comprise a 28 -day Screening Period and 
3treatment periods. These subjects will receive 3 doses of maribavir separated b y a least a 
72-hour washout period between doses: in Treatment Period 1 on Day 1, they  will receive a 
single oral dose of 400mg of maribavir; in Treatment Period 2 and Treatment Period 3 on Day 1, 
they will be randomized to receive a single oral dose of 200 mg followed by  800 mg of maribavir 
or a single oral dose of 800 mg followed b y 200 mg maribavir ( Table 1,Table 2,Table3
, and 
Table 4). 
All subjects (Japanese and Caucasian) can have their ty pical diet prior to the study ; all subjects 
(Japanese and Caucasian) will receive identical meals on Day
 1 (up to 24 hours post dose) in all 
treatment periods to maintain control. All maribavir doses will be administered with a glass 
(240 mL) of room temperature water after at least a 10 -hour overnight fasting, with water 
restricted 1 hour before and 1 hour after dosing. Food will be provided to subjects approximately  
4hours after study  drug administration. ( Assessing the Effects of Food on Drugs in INDs and 
NDAs –Clinical Pharmacology  Considerations, 2019). Vomiting occurring within 4 hours after 
dosing will be recorded. There will be at least a 72- hour washout between maribavir d oses for 
the subjects of Japanese descent.
The study  duration for the non
-Hispanic, Caucasian cohort will comprise a 28- day screening 
period and Treatment Period 1. For the subjects of Japanese descent, the study  duration will 
comprise a 28- day screening p eriod and Treatment Periods 1, 2, and 3. For both groups 
(Japanese and Caucasian subjects), there will be a post- treatment follow -up telephone call at 
7(±4) day s after the last dose of IP.
The total number of nights subjects will be expected to stay  at th e CRC is approximately  2 for 
the non- Hispanic, Caucasian subjects and approximately  8 for the subjects of Japanese descent. 
Shire CONFIDENTIAL Page 35
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
The maximal total duration of study  participation for a non -Hispanic, Caucasian subject is 
approximately  37 day s and approximately  47 days for the subjects of Japanese descent, if the 
screening, treatment, washout, and follow-up visit durations are used.
Treatment Period:
In Treatment Period 1, all study  subjects (both Japanese and Caucasian) will receive 
maribavir as a single 400 mg o ral dose. For the non -Hispanic, Caucasian group there 
will be only  one treatment period.
In Treatment Periods 2 and 3, all subjects of Japanese descent will receive maribavir 
as a single oral dose of either 200 mg or 800 mg, depending upon randomization 
assignment.
Pharmacokinetic Assessments
Serial blood samples for PK analy sis will be collected in each treatment period for the 
determination of maribavir and  plasma concentrations at pre- dose and up to 
approximately  24 hours post dose. These blood samples will be collected according to 
the Schedules of Assessments ( Table 1, 
Table 2, Table 3, Table 4, Table 5, and 
Table 6).
Safety Assessments
Safety  and tolerability  will be determined through assessment of TEAEs from the first 
dose to the post -treatm ent follow -up telephone call at 7 (±4) day s after the last dose 
of IP, and vital signs, ECG, and clinical laboratory evaluations on Day  1 pre -dose and 
up to 24 hours post dose in each treatment period . 
Follow -up
A post -treatment follow -up telephone call will occur at 7 (±4) day s after the last dose 
of IP for each subject. Subjects who experience AEs will be followed longer if 
needed, including an unscheduled clinic visit if appropriate, depending on the nature, 
severit y, and seriousness of the AE.
Rationale for Study Design and Dose Selection
Maribavir 400 mg BID is the clinical dose currently  being evaluated in the ongoing 
pivotal Phase 3 studies; therefore, a single oral dose of 400 mg maribavir was 
selected for evaluating the primary  objective of this study  –to compare maribavir PK 
between Japanese and Caucasian subjects. Maribavir has demonstrated 
time-independent PK and a favorable safet y profile in previous Phase 1 studies. 
Therefore, evaluating PK following repeated dosing, eg, 400 mg BID, is not 
necessary  in this study . Although dose proportionality  of PK for doses from 50 mg up 
to 900 mg was demonstrated in previous studies in Caucasian subjects, to explore the 
appropriate clinical dosage in Japanese subjects the lower and higher dosages were 
also selected to assess dose proportionality  and to support the future Phase 3 clinical 

Shire CONFIDENTIAL Page 36
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
development of maribavir in Japanese subjects. Therefore, the secondary  objective of 
the study  was to evaluate dose proportionality  of maribavir PK in subjects of 
Japanese descent. The doses of 200, 400, and 800 mg were selected for evaluating 
dose proportionality as a more than two-fold differences in systemic exposure to 
maribavir is not expected in Japanese subjects as compared to Caucasian sub
jects. As 
the primary  objecti ve is to compare maribavir PK at 400 mg, the 400 mg dose is to be 
evaluated in Treatment Period 1 in both Japanese and Caucasian subjects to avoid 
treatment period effects on this comparison. 
Shire CONFIDENTIAL Page 37
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Figure 1Study Design Flow Chart
This is an open -label study  to evaluate the PK, safety , and tolerability  of single doses of maribavir in healthy , adult subjects of 
Japanese descent and matched, health y, adult, non -Hispanic, Caucasian subjects. These cohorts of healthy , non- Hispanic, Caucasian 
subjects and health y Japanese subjects need not be dosed at the same time.
*Washout period of 72 to 73 hours after treatment on Day 1.

Shire CONFIDENTIAL Page 38
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
3.2 Maximum Duration of Participation and Study Completion
The maximum duration of participation for non-Hispanic, Caucasian subjects is expected to be 
approximately  37 day s, and the maximum duration of participation for subjects of Japanese 
descent is expected to be approximately  47 day s, if the maximum screening, treatment, washout, 
and follow -up durations are used. The study  will be c ompleted in approximately 1 month to 
2months.
The Study  Completion Date is defined as the date on which the last subject in the study  
completes the final protocol -defined assessment(s). Please note that this includes the follow-
up 
visit or contact, whiche ver is later (refer to Section 7.1.4 for the defined follow -up period for this 
protocol).
3.3 Sites and Regions
This study  will be conducted at a single site in the United States (US).
Shire CONFIDENTIAL Page 39
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
4. STUDY POPULATION
Each subject must participate in the informed consent proc ess and provide written informed 
consent/assent before any procedures specified in the protocol are performed.
4.1 Inclusion Criteria
The screening period starts with the signing of the informed consent. During the screening 
period, inclusion/exclusion criteri a for study  participation will be checked/tested. The subject 
will not be considered eligible for the study without meeting all of the criteria below.
Subjects cannot be enrolled or randomized before all inclusion criteria (including test results) are 
confirmed.
1.An understanding, ability, and willingness to full y comply  with study  procedures and 
restrictions. 
2.Ability  to voluntaril y provide written, signed, and dated (personally or via a 
legally -authorized representative) informed consent/assent as applicab le to participate in 
the study .
3.Health y subjects of Japanese descent must have been born in Japan and must not have 
lived outside of Japan for >10 y ears; both parents and all 4 grandparents must be of 
Japanese origin. Health y, non- Hispanic, Caucasian subje cts must have both parents and 
all 4 grandparents of non -Hispanic, Caucasian origin.
4.Age 18 to 55 y ears inclusive, at the time of consent. The date of signature of the informed 
consent is defined as the beginning of the screening period. This inclusion cri terion will 
only be assessed at the first screening visit.
5.Male, or non- pregnant, non -breastfeeding female who agrees to comply  with any  
applicable contraceptive requirements of the protocol or females of non -childbearing 
potential. 
6.Health y as determined by the investigator on the basis of screening evaluations. Healthy  
status is defined by  absence of evidence of any  active or chronic disease following a 
detailed medical and surgical history , a complete phy sical examination including vital 
signs, 12 -lead E CG, hematology , blood chemistry  (includes thy roid stimulating hormone 
[TSH] and free T4 at screening only ), and urinalysis.
7.Hemoglobin for males 135.0 g/L and females 120.0 g/L at screening and on Day  -
1.
8.BMI between 18.5 and 28.0 kg/m2 inclusive with a body  weight >45 kg (99 lbs.). This 
inclusion criterion will only  be assessed at the first screening visit.
9.Ability  to swallow a dose of I P.
4.2 Exclusion Criteria
The subject will be excluded from the stud y if an y of the following exclusion criteria are met. 
Shire CONFIDENTIAL Page 40
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
1.History  of any  hematological, hepatic, respiratory, cardiovascular, renal, neurological, or 
psychiatric disease, gall bladder removal, or current recurrent disease that could affect the 
action, absorption, or disposition of the I P, or clinical or laboratory  assessments.
2.Current or relevant history  of phy sical or ps ychiatric illness, any medical disorder that 
may require treatment or make the subject unlikely  to full y complete the study, or an y 
condition that presents undue risk from the IP or proce dures.
3.Known or suspected intolerance or h ypersensitivity to maribavir, closel y-related 
compounds, or an y of the stated ingredients.
4.Significant illness, as judged b y the investigator, within 2 weeks of the first dose of I P.
5.Donation of blood or blood prod ucts (eg, plasma or platelets) within 60 day s prior to 
receiving the first dose of I P.
6.Have taken another IP within 30 day s or five half -lives of that I P, whichever is greater, 
prior to the first dose of maribavir.
7.Have been enrolled in a clinical study  (including vaccine studies) within 30 day s prior to 
the first dose of IP that, in the investigator's opinion, may  impact this study .
8.Have had an y substantial changes in eating habits within 30 days prior to the first dose of 
IP, as assessed b y the investigat or.
9.Confirmed sy stolic blood pressure >139 mmHg or <89 mmHg, and diastolic blood 
pressure >89 mmHg or <49 mmHg.
10.Twelve -lead ECG demonstrating QTc >450 msec at screening. If QTc exceeds 450 msec, 
the ECG should be repeated 2 more times and the average of th e 3 QTc values should be 
used to determine the subject’s eligibility . 
11.Known history  of alcohol or other substance abuse, including s ynthetic cannabinoids 
within the last y ear.
12. Male subjects who consume more than 21 units of alcohol per week or 3 units per day. 
Female subjects who consume more than 14 units of alcohol per week or 2 units per day . 
(1 alcohol unit=1 beer or 1 wine [5 oz/150 mL] or 1 liquor [1.5 oz/40 mL] or 0.75 oz 
alcohol).
13. A positive urine test for drugs of abuse, alcohol, or cotinine at sc reening or on Day  -
1.
14. A positive HIV, hepatitis B surface antibody  (HBsAg), or hepatitis C virus (HCV) 
antibody  screen.
15.Use of tobacco in an y form (eg, smoking or chewing) or other nicotine -containing 
products in an y form (eg, gum, patch). Ex -users must re port that they  have stopped using 
tobacco for at least 30 days prior to receiving the first dose of I P.
16.Routine consumption of more than 2 units of caffeine per day  or subjects who experience 
caffeine withdrawal headaches. (1 caffeine unit is contained in the following items: one 
6oz [180 mL] cup of coffee, two 12 oz [360 mL] cans of cola, one 12 oz cup of black 
tea, and three 1 oz [85 g] chocolate bars. (Decaffeinated coffee, herbal tea, or cola are not 
considered to contain caffeine).
17.Prior screen failur e, randomization, enrollment, or participation in this study.
18.Current use of an y prescription medication (with the exception of hormonal replacement 
therap y, hormonal contraceptives, and occasional use of ibuprofen and/or 
acetaminophen) within 30 day s of t he first dose of I P. Current use of an y over the counter 
medication (including herbal preparations like St. John’s wort and ginkgo biloba, or 
homeopathic preparations) within 14 day s of the first dose of I P.
Shire CONFIDENTIAL Page 41
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
19.Ingestion of known CYP 3A modulators within 7 da ys of Day  1, Period 1 (includes 
grapefruit or grapefruit juice, oranges, Seville oranges, vegetables from the mustard green 
family  [eg, kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, 
mustard], charbroiled meats, and products contai ning these ingredients).
20.History  of active or chronic oral/nasal cavity infections, gastroesophageal reflux, asthma 
treatment with albuterol, zinc supplementation.
21.Subjects with dry  mouth sy ndrome or burning mouth sy ndrome or menopausal women 
suffering from dy sgeusia.
22.Subjects who have acute GI sy mptoms at screening or admission (eg, nausea, vomiting, 
diarrhea, and heartburn).
4.3 Restrictions
All subjects (Japanese and Caucasian) can have their ty pical diet prior to the study ; all subjects 
(Japanese and Cau casian) will receive identical meals on Day  1 (up to 24 hours post dose) in all 
treatment periods to maintain control.
Subjects should refrain from the following:
1.Strenuous phy sical exercise 48 hours prior to admission to the CRC and during the 
in-house st ays at the CRC.
2. Consuming grapefruit or grapefruit juice, oranges, Seville oranges, and products 
containing these items, vegetables from the mustard green family  [eg, kale, broccoli, 
watercress, collard greens, kohlrabi, Brussels sprouts, mustard], charbro iled meats, and 
products containing these ingredients) and products containing these items from 7 days 
prior to Day  1 of the first treatment period through the completion of the last treatment 
period. 
3.Consuming pine nuts 7 day s prior to Day  1 of the first treatment period through the 
completion of the last treatment period.
4.Consuming alcohol 48 hours prior to admission to the CRC and during the in -house stay  
at the CRC.
5.Use of tobacco or an y products containing nicotine within 30 days of Day  1 of the firs t 
treatment period through the completion of the last treatment period.
6.Taking or regularl y using any prescription medication with the exception of those listed 
in Section 5.2.1 from 30 day s prior to receiving the first dose of the I P through the 
completio n of the discharge assessments and procedures, and over the counter 
medications (including over -the counter multi -vitamin, herbal, or homeopathic 
preparations) from 14 days prior to receiving the first dose of the IP through the 
completion of the discharge assessments and procedures. Subjects should not use 
antacids, proton pump inhibitors, H2 antagonists, or zinc supplementation. 
7.Foods or beverages containing caffeine/xanthine 48 hours prior to admission to the CRC 
and during the in -house stay  at the CRC.
4.4 Reproductive Potential
4.4.1 Female Contraception
There is no clinical experience with maribavir in pregnant subjects.  
Shire CONFIDENTIAL Page 42
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Sexually  active females of child -bearing potential must be advised to use an acceptable method 
of contraception throughout the study  period and for 30 day s following the last dose of I P. 
Females of child -bearing potential who are not currentl y sexually act ive must agree to use 
acceptable contraception, as defined below, if they become sexually  active during the period of 
the study  and 30 day s following the last dose of IP. 
Female subjects should be either:
 Post-menopausal (12 consecutive months of spontaneous amenorrhea and 
age50years), or
 Surgicall y sterile (having undergone one of the following surgical procedures: 
hysterectom y, bilateral tubal ligation, bilateral oophorectom y or bilateral 
salpingectomy) and at least 6 weeks post -sterilization, or
 All females of child -bearing potential with a negative serum beta -human chorionic 
gonadotropin ( -HCG) pregnancy  test at the screening visit and prior to randomization 
or enrollment. Females of child- bearing potential must agree to abstain from sexual 
activity  that could result in pregnancy  or agree to use acceptable methods of 
contraception.
Acceptable methods of contraception are:
 Intrauterine devices plus condoms
 Double- barrier methods (eg, condoms and diaphr agms with spermicidal gel or foam)
 Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for 
at least 30 day s prior to the first dose of IP, plus condoms. Note: if subject becomes 
sexually  active during the study , they  should use one of the other acceptable methods 
noted above in addition to the hormonal contraceptive until it has been stabilized for 
30days. If hormonal contraceptives are used they  should be administered according to 
the package insert.
4.4.2 Male Contraception
Male subjects will be required to use a condom in conjunction with spermicidal gel, foam, 
cream, film, or suppository  from time of dosing until 3 months after the last dose of I P. 
Childbearing female partners of male stud y participants will be required to follow the acceptable 
methods of contraception for this study  (described in Section 4.4.1) from the time of first dosing 
until 3 months after the last dose of IP. For male subjects, sexual intercourse with pregnant 
partners should also be avoided during the course of the study  unless condoms are used from the 
time of the first dose until 3 months after the last dose of IP. Male subjects must not donate 
sperm until 3 months after the last dose of IP.
4.5 Discontinuation of Subjects
A subject may  withdraw from the study  at any  time for an y reason without prejudice to his/her 
future medical care b y the physician or at the institution, or may  be withdrawn at any  time at the 
Shire CONFIDENTIAL Page 43
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
discretion of the investigator or sponsor (eg, in the interest of subject safety). The investig ator is 
encouraged to discuss withdrawal of a subject with the medical monitor when possible.
If IP is discontinued, regardless of the reason, the early withdrawal evaluations listed in Table 1
and Table 5are to be performed as completely  as possible. Whe never possible, all discontinued 
subjects should also undergo follow -up evaluations. Comments (spontaneous or elicited) or 
complaints made by  the subject must be recorded in the source documents. The reason for 
discontinuation, date of discontinuation of t he IP, and the total amount of IP administered must 
be recorded in the source documents and the case report form (CRF). 
Subjects who discontinue earl y without completing all planned PK assessments for Treatment 
Period 1 may  be replaced at the sponsors discretion to ensure at least 24 subjects (12 subjects of 
Japanese descent and 12 matching, non -Hispanic, Caucasian subjects) with evaluable PK for the 
statistical analy sis of the primary  objective (PK comparison between Japanese and non- Hispanic, 
Caucasian s ubjects). If subjects discontinue earl y during Treatment Period 2 or 3, there is no 
need for replacement. 
4.5.1
Reasons for Discontinuation
The reason for discontinuation must be determined by  the investigator and recorded in the 
subject’s source document. I f asubject discontinued for more than 1 reason, each reason should 
be documented in the source document and the most clinically  relevant reason should be 
indicated.
Reasons for discontinuation include but are not limited to:
AE
Protocol deviation
Withdrawal by subject 
Lost to follow -up
Other (The investigator must specify  on the CRF)
4.5.2 Subjects ‘Lost to Follow -up’ Prior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact an y subject lost to follow -up at 
any time point prior to the last scheduled contact (office visit or telephone contact). At least 1 of 
these documented attempts must include a written communication sent to the subject’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking th at they  
return to the site for final safet y evaluations and return any unused IP.
Shire CONFIDENTIAL Page 44
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
5. PRIOR AND CONCOMITAN T TREATMENT
5.1 Prior Treatment
Prior treatment includes all treatment (including but not limited to herbal treatments, vitamins 
non-pharmacological treatments such as ps ychotherap y as appropriate) received within 30 days 
(or PK equivalent of 5 half -lives, whichever is longer) of the date of first dose of IP. Prior 
treatment information must be recorded on the appropriate CRF page.
5.2 Concomitant Treatment 
Concomitant treatment refers to all treatment taken between the dates of the first dose of IP and 
the end of the follow -up period, inclusive. Concomitant treatment information must be recorded 
on the appropriate CRF page.
5.2.1 Permitted Treatment
Subjects should refrain from taking an y medications (excluding those medications listed below) 
during the course of the study . Any medication which is considered necessary  for the subject’s 
safet y and wellbeing may be given at the discretion of the investigator. The administration of all 
medications (including IPs) must be listed on the appropriate CRF page.
Medications permitted during the stud y are li sted below:
Hormonal contraceptives for females of child -bearing potential administered according to the 
package insert (Section 4.4.1 )
Hormone replacement therap y
Occasional use of ibuprofen and/or acetaminophen
5.2.2 Prohibited Treatment
Refer to Section 4.3on restrictions for prohibited treatments.
Shire CONFIDENTIAL Page 45
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
6. INVESTIGATIONAL PROD UCT
6.1 Identity of Investigational Product
The I P is maribavir, which will be provided in tablet form. 
Maribavir tablets are blue, film- coated tablets containing 200 mg of maribavir. The tablets a re 
packaged in a 60 cc, white, high -density  polyethylene (HDPE) bottle containing 40 tablets. 
Additional information and detailed instructions are provided in the maribavir IB, and in a 
Pharmacy  Manual that will be provided.
The sponsor will provide the I P.
6.1.1 Blinding the Treatment Assignment
Not applicable. This is an open-label stud y.
6.1.2 Unblinding the Treatment Assignment
Not Applicable. This is an open-label stud y.
6.2 Administration of Investigational Product(s)
6.2.1 Allocation of Subjects to Treatment
This is an 
open -label, randomized study . The actual treatment given to individual subjects is 
determined b y a randomization schedule.
The subjects of Japanese descent will receive 3 doses of maribavir separated by  a 72 -hour 
washout period between doses: in Treatment Period 1 on Day 1, they  will receive a single oral 
dose of 400 mg of maribavir; in Treatment Period 2 and Treatment Period 3 on Day  1, they  will 
be randomized to receive a single oral dose of either 200 mg followed b y 800 mg of maribavir in 
a crossover stu dy design.
Subject numbers are assigned to all subjects as they consent to take part in the study . The subject 
number is assigned to subjects according to the sequence of presentation for study  participation. 
A 4-digit randomization number, , will be allocated immediately  prior to dosing 
after eligibility  has been determined. Once a randomization number has been assigned, that 
number must not be used again if, for example, a subject is withdrawn from the study. For 
randomized subjects, the randomization number will be the identifying number used throughout 
CRF.  If a randomization number/unique identifier is allocated incorrectl y, the clinical research 
associate (CRA)/study monitor must be notified as soon as the error is discovered.
Screen failures will not be captured for this stud y.
The randomization number represents a unique number corresponding to I P allocated to the 
subject prior to dosing after eligibility  has been determined.

Shire CONFIDENTIAL Page 46
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
6.2.2 Dosing
The non- Hispanic, Caucasian subjects will receive a single oral dose of 400 mg maribavir 
(2×200 mg maribavir tablets) on Day  1. The Japanese subjects will receive 3 doses of maribavir: 
on Day 1 of Treatment Period 1, they  will receive a single oral dose of 400 mg of maribavir 
(2×200 mg maribavir tablets); on Day  1 of Treatment Period 2, they will be randomized to 
receive a single oral dose of either 200 mg (1×200 mg tablets) or 800 mg of maribavir 
(4×200 mg maribavir tablets); and on Day  1 of Treatment Period 3, they  will receive a single oral 
dose of whichever dosage they  did not receive on D ay 1 of Treatment Period 2 (200 mg or 
800mg).  
6.2.3 Administration
All subjects (Japanese and Caucasian) can have their ty pical diet prior to the study ; all subjects 
(Japanese and Caucasian) will receive identical meals on Day 1 (up to 24 hours post dose) in all 
treatment periods to maintain control. All maribavir doses will be administered with a glass 
(240 mL) of room temperature water after at least a 10 -hour overnight fasting, with water 
restricted 1 hour before and 1 h our after dosing. Food will be provided to subjects approximately  
4hours after stud y drug administration. Vomiting occurring within 4 hours after dosing will be 
recorded. There will be at least a 72 -hour washout between maribavir doses for the subjects of
Japanese descent (Assessing the Effects of Food on Drugs in INDs and NDAs –Clinical 
Pharmacology  Considerations
, 2019).
6.3 Labeling, Packaging, Storage, and Handling
6.3.1 Labeling
Labels containing study  information and pack identification are applied to the I P container.
All IP (maribavir) is labeled with a minimum of the protocol number, medication identification 
number (if applicable), dosage form (including product name and quantity  in pack), directions 
for use, storage conditions, batch number and/or packagi ng reference, the statements “For 
clinical trial use only ” and/or “CAUTION: New Drug –Limited b y Federal (or US) Law to 
Investigational Use” and “Keep out of reach of children,” and the sponsor’s name and address.
Additional labels (eg, those used when di spensing marketed product) may , on a case
-by-case 
basis, be applied to the IP in order to satisfy  local or institutional requirements, but must not:
Contradict the clinical study  label
Obscure the clinical study label
Identify  the study  subject by  name
Additional labels may  not be added without the sponsor’s prior full agreement.
Shire CONFIDENTIAL Page 47
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
6.3.2 Packaging
Investigational product is packaged in the following labeled container:
Maribavir tablet: 60 cc, white, square, HDPE bottle
Changes to sponsor -supplied packaging prior to dosing may  not occur without full agreement in 
advance b y the sponsor.
6.3.3 Storage
The investigator has overall responsibility  for ensuring that IP is stored in a secure, limited 
access location. L imited responsibility  may  be delegated to the pharmacy  or memb er of the stud y 
team, but this delegation must be documented. Investigational products are distributed by  the 
pharmacy  or nominated member of the study  team. The pharmacist/nominated team member will 
enter the unique subject identifier (if allowed b y law/r egulations) on the IP bottle/carton labels as 
they are distributed.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the I P is maintained 
within an established temperature range. The investigator is responsible for ensuring that the 
temperature is monitored throughout the duration of the study  and that records are maintained; 
the temperature should be monitored continuously by  using either an in -house sy stem, a 
mechanical recording device such as a calibrated chart recorder, or b y manual means, such that 
both minimum and maximum thermometric values over a specific time period can be recorded 
and retrieved as required. Such a device (ie, certified min/max thermometer) would require 
manual resetting upon each recording. The sponsor must be notified immediately  upon discovery  
of an y excursion from the established range. Temperature excursions will require site 
investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the I P and will provide supportive documentation as necessary . Under no 
circumstances should the product be dispensed to subjects until the impact has been determined 
and the product is deemed appropriate for use b y the sponsor.
The sponsor should be notified immediately  if there are an y changes to the storage area of the IP 
that could affect the integrity  of the product(s), eg, fumigation of a storage room.
6.4 Drug Accountability
Investigators wi ll be provided with sufficient amounts of the I P to carry  out this protocol for the 
agreed number of subjects. The investigator or designee will acknowledge receipt of the IP, 
documenting shipment content and condition. Accurate records of all IP dispensed , used, 
returned, and/or destro yed must be maintained as detailed further in this section.
The investigator has overall responsibility  for administering/dispensing I P. Where permissible, 
tasks may  be delegated to a qualified designee (eg, a pharmacist) who is adequatel y trained in the 
protocol and who works under the direct supervision of the investigator. This delegation must be 
documented in the applicable study  delegation of authority  form.
Shire CONFIDENTIAL Page 48
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
The investigator or his/her designee (as documented by  the investigator in the applicable stud y 
delegation of authorit y form) will dispense the I P only  to subjects included in this study  
following the procedures set out in the study  protocol. Each subject will be given onl y the IP 
carrying his/her treatment assignment. All dispensed medication will be documented in the 
subject's source and/or other IP record. 
No IP stock or returned inventory  from a Shire -sponsored study  may  be removed from the site 
where originally  shipped without prior knowledge and consent by  the sponsor. If such transfer is 
authorized by  the sponsor, all applicable local, state, and national laws must be adhered to for the 
transfer.
The sponsor or its representatives must be permitted access to review the supplies storage and 
distribution procedures and records.
With the written agreement of the sponsor, at the end of the study  all unused stock and 
empty /used IP packaging may  be destroy ed at the site or a local facility . In this case, destruction 
records identify ing what was destroy ed, when and how, must be obtained with copies provided 
to the sponsor. Destruction of I P must be in accordance with local, state, and national laws.
Based on entries in the site drug accountability  forms, it must be possible to reconcile I P 
delivered with those used and re turned. All I P must be accounted for and all discrepancies 
investigated and documented to the sponsor’s satisfaction.
6.5 Subject Compliance
Compliance must be assessed by  observation of dosing by  the investigator or designee. In 
addition, the CRC personnel sh ould perform a hand and mouth check of the subject to assure the 
IP has been ingested. The investigator/nominated person will record details on the drug 
accountability  log(s) and/or source documents. In addition, details of the dosing time (time, date, 
dose level) will be captured in the appropriate CRF.
6.6 Retention of Bioavailability and Bioequivalence Testing Samples
Not applicable.
Shire CONFIDENTIAL Page 49
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
7. STUDY PROCEDURES
7.1 Study Schedule
See Table 1, Table 2, Table 3, Table 4, Table 5, and Table 6for stud y procedures. 
The follow ing “priorit y order” will be in effect when more than 1 procedure or assessment is 
required at a particular time point.
Spontaneous or solicited AE reporting
ECG
Vital signs
PK blood sampling
Clinical laboratory  tests
Physical examination.
NOTE: Blood 
sampling for PK evaluation must be performed at the precise protocol -scheduled 
time. Actual sampling time(s) must be accurately recorded in the source document and 
appropriate CRF.
7.1.1 Screening Period
Written, signed, and dated informed consent from the subje ct prior to the performance of an y 
study -related procedures must be obtained by  the principal investigator or a designee. A copy  of 
the signed informed consent and assent form must be given to the subject for their records.
Screening procedures must be com pleted within 28 day s of Day  1 as appropriate, prior to 
receiving the first dose of IP. All screening assessments and procedures are to be performed by  
the principal investigator or a qualified designee. See Table 1and Table 5for a complete list of 
scree ning procedures to be performed.
7.1.1.1 Screening Failure
A screen failure is a subject who has given informed consent and failed to meet the inclusion 
and/or met at least 1 of the exclusion criteria and has not been randomized or administered IP.
For purposes of data collection, all subjects who give consent to the study , but are not enrolled 
and/or randomized will be reported as screen failures even if they  were otherwise full y eligible 
for the study, for example alternates/reserve subjects.
7.1.1.2 Rescreening of Subje cts
Subjects who fail to meet all inclusion/exclusion criteria may  be permitted to be rescreened for 
the study  at the discretion of the study  Principal Investigator in consultation with the Shire Study  
Medical Monitor. 
Shire CONFIDENTIAL Page 50
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Eligible subjects who meet all inclu sion/exclusion criteria, but are unable to participate in the 
study  due to scheduling conflicts/timing, may  be rescreened based on investigator discretion and 
Sponsor approval should their availability  to participate fall outside the screening window. In 
these cases, a new screening number must be assigned for each subject who is rescreened and a 
new informed consent form must be signed.
7.1.2 Predose Assessments
Following the screening visit, eligible subjects will return to the CRC on Day  -1 of the stud y. 
Predose assessments, including check -in to the CRC will be performed on Day  -1, as described 
in Table 1, Table 2
, Table 3, Table 4 , Table 5, and Table 6.
7.1.3 Treatment Periods 
The non-Hispanic, Caucasian subjects will have one Treatment Period. The Japanese subjects 
will have Treatment Periods 1, 2, and 3. 
7.1.3.1 Treatment Period 1 (Non- Hispanic, Caucasian Subjects)
Study  assessments for non -Hispanic, Caucasian Subjects Day s 1 and 2 i n Treatment Period 1 are 
outlined in Table 5and Table 6
.Administration of maribavir will occur on Day  1 as described in 
Section 6.2.2. Non- Hispanic, Caucasian subjects will be discharged from the CRC on Day 2. 
7.1.3.2 Treatment Period 1 (Japanese Subjects)
Study assessments for Japanese subjects on Day s 1 and 2 in Treatment Period 1 are outlined in 
Table 1and Table 2. Administration of maribavir will occur on Day  1, as described in 
Section 6.2.2. There will be a 72-hour washout period after administration of th e IP on Day 1. 
7.1.3.3 Treatment Period 2 (Japanese Subjects)
Study  assessments for Japanese subjects on Day s 1 and 2 in Treatment Period 2 are outlined in 
Table 1and Table 3
.Administration of maribavir will occur on Day  1, as described in 
Section 6.2.2. There will be a 72-hour washout period after administration of the I P on Day 1. 
7.1.3.4
Treatment Period 3 (Japanese Subjects)
Study  assessments for Japanese subjects on Day s 1 and 2 in Treatment Period 3 are outlined in 
Table 1and Table 4. Administration of maribavir will occur on Day  1, as described in 
Section 6.2.2. Japanese subjects will be discharged from the CRC on Day 2.
7.1.4 Follow -up Period (All Subjects)
There will be a follow -up telephone call at 7 (±4) day s after the last dose of I P to query  for 
SAEs, AEs, and c oncomitant treatments. Subjects who experience AEs will be followed longer if 
needed, including an unscheduled clinic visit if appropriate, depending on the nature, severit y, 
and seriousness of the AE. All AEs and SAEs that are not resolved at the time of this contact will 
be followed to closure ( Appendix 2.2 ).
Shire CONFIDENTIAL Page 51
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
7.1.5 Additional Care of Subjects After the Study
No after care is planned for this study .
7.2 Study Evaluations and Procedures
7.2.1 Demographic and Other Baseline Characteristics
Subject demographic information including date of birth, sex, age, race, and ethnicity  will be 
collected at the initial screening visit, prior to the subject receiving the first dose of IP. 
7.2.1.1 Height and Weight
Height and weight will be measured and recorded in the subject’s source documents. 
7.2.2 Safety
The name and address of each third part y vendor (eg, clinical laboratory ) used in this study  will 
be maintained in the investigator’s and sponsor’s files.
Actual safety  assessment times will be monitored and reco rded. The sponsor’s expectation is that 
the investigator will ensure that every  effort is made to perform all assessments at the 
protocol -scheduled time. Any  safet y assessment that deviates from the scheduled assessment 
time set forth in the protocol by  more than  15 minutes will be considered a protocol deviation.
Adverse events (defined as AEs occurring from the time of informed consent signature to first 
dose of IP), TEAEs (all AEs occurring after the first treatment or worsening after the first 
treatmen
t), prior medication, and concomitant medication use will be assessed and monitored 
from the time the subject signs the informed consent form to completion of study  (including to 
time of screen failure or dropout/discontinuation). While confined in the CRC , subject safety will 
also be closel y monitored through blood pressure measurements, ECG measurement, clinical 
safet y labs, and ph ysician oversight.
7.2.2.1 Medical and Medication History
A complete medical and medication history, as well as demographic information, will be 
performed at the Screening Visit/time points described in Table 1, Table 2, Table 3, Table 4, 
Table 5, and Table 6by a qualified licensed ph ysician, phy sician’s assistant, or a nurse 
practitioner. The medical and medication history  will be coll ected and recorded in the subject’s 
source documents. The medical history  will include:
History  of respiratory , cardiovascular, renal, GI, hepatic, endocrine, hematological, 
neurological, ps ychiatric, and other disease s
Recent ingestion of medication (30 d ays prior to entering the Screening Period)
Record medications taken via I njection/Infusion (IV, IM, SQ) ie, insulin, vaccine, etc. 
Shire CONFIDENTIAL Page 52
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
7.2.2.2 Physical Examination (Including Height and Weight)
A complete ph ysical examination will be performed at the time points des cribed in Table 1, 
Table 2, Table 3, Table 4, Table 5, and Table 6by a qualified licensed ph ysician, phy sician’s 
assistant, or a nurse practitioner.
The phy sical examination will include a review of the following bod y systems:
General appearance
Skin
Head, ey es, ears, nose, and throat
Spine/neck/thy roid
Musculoskeletal
Respiratory
Cardiovascular
Neurological
Abdomen (including liver and kidney s).
If more than 2 day s have passed since screening, a phy sical examination should be repeated on 
Day -1. Abnormalities identified at the Screening Visit will be documented in the subject’s 
source documents and on the medical history  CRF. Changes after the Screening Visit will be 
captured as AEs on the AE CRF page, as deemed appropriate b y the investigator.
7.2.2.3 Adverse Event Collection
At each stud y visit and at the post -treatment follow -up telephone call, subjects will be questioned 
in a general way  to ascertain if AEs have occurred since the previous visit (eg, “Have you had 
any health problems since y our last vi sit?”). Adverse events are collected from the time informed 
consent is signed. (Refer to Appendix 2for AE definitions, assessment, collection time frame, 
and reporting procedures.)
7.2.2.4 Vital Signs
Blood Pressure and Pulse Rate
Blood pressure and pulse rate w ill be measured at times specified in Table 1, Table 2
, Table 3, 
Table 4, Table 5, and Table 6 . Additional blood pressure and pulse rate measurements may  be 
performed, as determined by  the investigator, in order to ensure appropriate monitoring of 
subject safet y and accurate recording of vital sign measurements. An y changes from baseline 
which are deemed clinically  significant b y the investigator are to be recorded as an AE.
The same method for obtaining blood pressure measurement (auscultatory  or oscillome tric) 
should be used throughout the study  (and documented) for all subjects. In addition, the 
conditions of vital sign measurements should be controlled and as consistent as possible during 
Shire CONFIDENTIAL Page 53
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
the study , in order to minimize external variability of the readings. It is advised that 
measurements be collected at a comfortable room temperature with little to no background noise, 
using the same (appropriately sized) cuff placed at the same location of the same arm during the 
study . The bladder should be deflated (c alibrated for oscillometric method or manually  by 
auscultatory  method) at a rate of 2- 3 mmHg/s (and the first and last audible sounds recorded as 
systolic and diastolic pressure) after at least 5 minutes of rest in the supine position.
The cuff should have a bladder length that is 80% and a width that is at least 40% of arm 
circumference (a length -to-width ratio of 2:1). 
The subject should be asked to remove all clothing that covers the location of cuff placement. 
The subject should not have exercised or c onsumed coffee, black tea, cola, chocolate, alcohol, or 
nicotine within 30 minutes of collection. The subject should be instructed to relax as much as 
possible for at least 5 minutes prior to collection. The subject should remain quiet during this 
time and through the measurement.
The subject should be l ying comfortabl y, with the legs uncrossed. The arm should be supported 
with a pillow, such that the middle of the cuff on the upper arm is at the level of the right atrium 
(approximately  halfway  between the bed and the level of the sternum) .
At the Screening Visit, blood pressure should be compared between both arms. 
One reading in a supine position should be taken. When there is a consistent inter -arm difference 
in either SBP/DBP confirmed over 3 consecutive measurements (>10mmHg), the arm with the 
higher blood pressure should be used for inclusion at screening and the last measurement 
recorded in the CRF. The same (right or left) arm with the higher blood pressure will be used 
throughout the stud y. 
The use of automated devices for measuring pulse rate is acceptable although, when done 
manually , pulse rate will be measured in the brachial/radial artery  for at least 30 seconds. When 
the timing of these measurements coincides with a blood collection, blood pre ssure and pulse 
rate should be obtained prior to the nominal time of the blood collection.
Respiratory Rate
The subject should be in a comfortable position. The observer should hold the extremity  of the 
subject as a distraction for the patient (ie, pretend ing he/she is taking the subject’s radial pulse) 
and count the respiration for 1 minute. 
Body Temperature
Oral temperature should be taken b y placing a digital thermometer under the tongue for at least 
30
seconds and the temperature reported in degrees Ce lsius. Ty mpanic temperature may  also be 
used. 
Shire CONFIDENTIAL Page 54
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
7.2.2.5 Electrocardiogram
Twelve -lead ECGs will be performed at the times specified in Table 1, Table 2, Table 3
, Table 4, 
Table 5, and Table 6. All ECGs will be performed using the equipment supplied by  the CRC.
The following parameters will be recorded on the appropriate CRF page: heart rate, PR, RR, 
QRS, and QT intervals. The Fridericia's correction for QT interval (QTcF) will be derived from 
the data in the database. The investigator’s assessment of the ECG tra cing as normal or abnormal 
must be documented, and if abnormal, his/her determination of whether the abnormality  is 
clinically  significant or not, will be documented on the tracing and recorded in the CRF.
The subject should be asked to remove all clothing
that covers the location of lead placement.
The subject should not have exercised or consumed coffee, black tea, cola, chocolate, alcohol, or 
nicotine within 30 minutes prior to collection. The subject must be resting in the supine position 
for at least 5 minutes prior to collecting the ECG.
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads are placed in the 
same positions each time in order to achieve precise ECG recordings. 
Electrocardiogram recording, including a 10 second rhy thm strip, will be obtained approximately  
2minutes to 4 minutes apart for all assessments. The recordings should be immediately  assessed 
and if not valid, should be re peated in order to obtain a valid recording.
If QTc exceeds 450 msec, the ECG should be repeated 2 more times and the average of the 
3 QTc values and the average of other triplicate ECG measurements should be used and recorded 
in the CRF. I nvalid recording s will not be entered in the CRF.
To ensure safet y of the subjects, a qualified individual at the investigator site will make 
comparisons to baseline measurements.
If the QTcF interval (calculated online on site) is increased b y >45 msec from the baseline, or an 
absolute QTcF value is >500 msec for an y scheduled ECG, then 2 additional ECGs will be 
collected, approximately  2 minutes to 4 minutes apart, to confirm the original measurement. If 
either of the QTcF values from these repeated ECGs remains above th e threshold value 
(>45 msec from the baseline; or is >500 msec), then a single ECG must be repeated at least 
hourly  until QTcF values from 2 successive ECGs fall below the threshold value that triggered 
the repeat measurement. When triplicate ECGs are collected, the mean of the triplicate 
measurements should be used to trigger the decision to collect follow -up ECGs.
If QTcF values remain above 500 msec (or >45 msec from the baseline) for >4 hours (or sooner 
at the discretion of the investigator); or QTcF in tervals get progressively  longer, the subject 
should undergo continuous ECG monitoring. A cardiologist should be consulted if QTcF 
intervals do not return to <500 msec (or to <45 msec above the baseline) after 8 hours of 
monitoring (or sooner at the discre tion of the investigator).
Shire CONFIDENTIAL Page 55
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
If a machine -read QTcF value is prolonged, as defined above, repeat measurements may  not be 
necessary  if a qualified phy sician’s interpretation determines that the QTcF values are in the 
acceptable range.
7.2.2.6 Clinical Laboratory Test s
The name and address of each third part y vendor (eg, clinical laboratory ) used in this study  will 
be maintained in the investigator’s and sponsor’s files.
All clinical laboratory  tests will be performed according to the laboratory ’s standard procedures. 
The subject should not eat or drink an ything for at least 8 hours to 10 hours before having 
clinical laboratory  tests.
Reference ranges will be supplied by  the laboratory  and used to assess the results for clinical 
significance and out -of-range changes wh ich may be associated with, or constitute, an AE. The 
investigator should assess out -of-range clinical laboratory  values for clinical significance, 
indicating if the value(s) is/are not clinically  significant or clinicall y significant. Abnormal 
clinical la boratory  values, which are unexpected or not explained by  the subject’s clinical 
condition, may , at the discretion of the investigator or sponsor, be repeated as soon as possible 
until confirmed, explained, or resolved.
The following clinical laboratory  assessments will be performed: 
Biochemistry
Blood samples for serum biochemistry  will be collected into a serum separator tube at the time 
points described in Table 1
, Table 2, Table 3 , Table 4, Table 5, and Table 6. The following 
parameters will be assesse d: 
Sodium Phosphate -HCG a
Potassium Protein
Glucose(fasting) Carbon dioxide
Urea nitrogen Albumin
Creatinine Aspartate transaminase 
Calcium Alanine transaminase 
Chloride Gamma glutamy l transferase 
Thyroid stimulating hormone (TSH)aAlkaline phosphatase 
Thyroxine (free T4) Total bilirubin 
Triiodothy ronine (T3) Uric acid
aFemales only.
Shire CONFIDENTIAL Page 56
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Hematology
Blood samples for hematology  will be collected into a K 2EDTA tube at the time points described 
in Table 1, Table 2, Table 3, Table 4, Table 5, and Table 6. The following parameters will be 
assessed:
Hemoglobin Total neutrophils (absolute)
Hematocrit Eosinophils (absolute)
Red blood cells Monocy tes (absolute)
Platelet count Basophils (absolute)
White blood cell count; total and differential Lym phocy tes (absolute)
Urinalysis
A urine sample for urinaly sis will be collected at the time points described in Table 1, Table 2, 
Table 3, Table 4, Table 5, and Table 6. The following parameters will be assessed:
pH Blood Nitrites
Glucose Ketones Leukocy te esterase
Protein Bilirubin Specific gravit y
Microscopic examination will be conducted if protein and/or blood is/are detected during 
urinaly sis. At a minimum the microscopic examination will consist of red blood cells, white 
blood cells, casts, and bacteria. 
7.2.2.7 Pregnancy Test 
A pregnancy  test is performed on all females as outlined in Table 1andTable 5, or if pregnancy  
is suspected, or on withdrawal of the subject from the study .
7.2.2.8 Drug and Alcohol Screen
A urine screen for drugs of abuse and alcohol will be performed at the time points described in 
Table 1and Table 5. Additional drug and alcohol screens may  be performed at the investigator’s 
discretion.
Urine samples are to be tested for amphetamines, barbiturates, benzodiazepi nes, cannabinoids, 
cocaine, methadone, opiate metabolite, and phencyclidine.
Results of urine drug and alcohol screens will be reviewed and verified b y the study monitor, but 
will not be collected in the CRF database.
Any positive result for drugs of abuse , cotinine, or alcohol at screening or on Day  -1 will exclude 
the subject from further participation in the study .
Shire CONFIDENTIAL Page 57
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
7.2.2.9 Serology Screen 
At the Screening Visit, a blood sample will be drawn into a serum separator tube to test for the 
presence of HIV, HBsAg, and HCV antibod y. 
The test results must be confirmed negative prior to enrollment in the study. If a test result is 
positive, the subject will be excluded from entering the stud y. Results of the virology  screen will 
be reviewed and verified by  the study  moni tor, but will not be collected in the CRF database.
7.2.3 Pharmacokinetic Procedures
The name and address of the bioanal ytical laboratory (ies) for this study  will be maintained in the 
investigator’s files at the/each site and in the Trial Master File with the sponsor.
Actual PK blood sample collection times versus time of dosing will be recorded. The sponsor's 
expectation is that the investigator will ensure that every  effort is made to collect all PK blood 
samples at the precise protocol scheduled time. Pharmacokinetic blood collection must not 
deviate from the nominal collection time set forth in the protocol by  more than 5 minutes from 
samples drawn within 4 hours post- dose or b y more than 
15 minutes for samples drawn bey ond 
4hours post -dose. Samples drawn outside these parameters will be considered a protocol 
deviation. 
7.2.3.1 Blood Sample Collection and Handling Procedures
Blood samples will be collected at the time specified in Table 1, Table 2, Table 3, Table 4, 
Table 5, and Table 6to measure plasma concentrations of maribavir and  
. 
Blood sample collection, processing and handling instructions are provided in the L aboratory  
Manual.
7.2.3.2 Plasma Drug Assay Methodology
Plasma concentrations of maribavir and  will be measured using th e most current 
validated bioanal ytical method. I n addition, selected plasma samples may  be used to investigate 
incurred sample reproducibility  (full details will be described in the bioanaly tical study  plan). 
The presence of other metabolites or artifacts may be monitored or quantified as appropriate. 
Raw data will be stored in the archive of the designated bioanal ytical contract laboratory . 
7.2.4 Volume of Blood to be Drawn from Each Subject
The volume of blood intended to be drawn from each subject is presente d in Table 7.

Shire CONFIDENTIAL Page 58
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Table 7 Volume of Blood to be Drawn from Each Subject 
AssessmentApproxim ate 
Sample Volume (mL)Number of 
SamplesTotal Volume (mL)
Pharm acokinetic samples a442 (Japanese) 
14 (Caucasian) 168 mL (Japanese) 
56 mL (Caucasian) 
HBsAg, HIV, HCV 3.51 (Japanese) 
1 (Caucasian) 3.5 mL (Japanese) 
3.5 mL (Caucasian)
SafetyBiochemistry and 
-HCG b 58 (Japanese)
4 (Caucasian)68 mL (Japanese)
34 mL (Caucasian)
Hem atology 48 (Japanese)
4 (Caucasian)32 mL (Japanese)
16 mL (Caucasian)
Total mL271.5 mL (Japanese)
109.5 mL (Caucasian)
-HCG=beta -human chorionic gonadotropin; HBsAg=hepatitis B surface antigen; HCV=hepatitis C virus; 
HIV=human immunodeficiency virus
aIf a catheter is used, the first 1mL is to be discarded; then take 2mL into appropriate tube for pharmacokinetic 
sample. A total of 3mL of blood draw n has been used in determination of sample volume.
b-HCG testing for females only.
During this stud y, it is expected that approximately  271.5 mL of blood will be drawn from 
Japanese subjects and approximately  109.5 mL of blood will be drawn from Caucasian subjects 
regardless of sex.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may  vary  according to the instructions provided by  the manufacturer or laboratory  
for an individual assessment. When more than 1 blood assessment is to be done at the time 
point/period, if they  require the same t ype of tube, the assessments may  be combined.
Shire CONFIDENTIAL Page 59
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
8. DATA MANAGEMENT AND STATISTICAL METHODS
8.1 Data Collection
The investigators’ authorized site personnel must enter the information required by  the study  
CRF Completion Guidelines or similar for all data requiring transcription of the source . A study  
monitor will visit each site in accordance with the monitoring plan and review the CRF data 
against the source data for completeness and accuracy . Discrepancies between source data and 
data entered on the CRF will be addressed b y qualified site personnel. When a data discrepancy  
warrants correction, the correction will be made by  authorized site personnel. Data collection 
procedures will be discussed with the site at the site initiation visit and/or at the investigator’s 
meeting. It is expected that site personnel will complete the CRF entry  within approximately  
3business day s of the subject’s visit.
8.2 Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management plan. 
Quality  contr ol and data validation procedures are applied to ensure the validity  and accuracy  of 
the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
8.3 Data Handling
Not applicable to this study .
8.4 Statistical Analysis Process 
The study  will be anal yzed by  the sponsor or its agent.
The Statistical Analy sis Plan (SAP) will provide the statistical methods and definitions for the 
analysis of the PK and safety  data, as well as describe the approaches to be taken for 
summarizing other study  information such as subject disposition, demographics and baseline 
characteristics, IP exposure, and prior and concomitant medications. The SAP will also include a 
description of how missing, unused and spurious d ata will be addressed. 
To preserve the integrit y of the statistical anal ysis and study  conclusions, the SAP will be 
finalized prior to database lock.
All statistical analy ses will be performed using SAS(SAS I nstitute, Cary , NC 27513). 
Shire CONFIDENTIAL Page 60
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
8.5 Planned Interim A nalysis, Adaptive Design, and Data Monitoring Committee
There is no planned interim analysis, adaptive design, or Data Monitoring Committee in this 
study .
8.6 Study Population
TheEnrolled Set will consist of all subjects who have signed informed consent and a lso passed 
inclusion/exclusion criteria.
The Safety Set will consist of all subjects who receive an y amount of IP. Analy sis will be 
performed according to the treatment regimen actually received regardless of the randomized 
treatment regimen.
The Pharmacokinetic ( PK) Set will consist of subjects who receive at least 1 dose of study  drug 
and have evaluable post-dose maribavir PK data (defined as complete concentration- time profile 
to obtain meaningful estimates of PK parameters). The PK anal yses wil l be based on this 
analysis population.
Subjects who do not provide reliable concentration
-time profile (in 1 or more periods) may  be 
excluded from PK anal ysis (for the corresponding treatment period). 
8.7 Pharmacokinetic Analyses
8.7.1 Pharmacokinetic Endpoint(s)
A PK evaluation of maribavir concentrations and  will be performed 
based on the PK Set. Pharmacokinetics parameters will be estimated for maribavir and  
following the administration of maribavir 400 mg for non- Hispanic, Caucasi an subjects and of 
200, 400, and 800 mg for subjects of Japanese descent.
Maribavir C max, AUC last, and AUC 0-infwill be the primary  endpoints.  
PK parameters will include, but not be limited to the follow ing:
Cmax Maximum observed plasma concentration 
tmax Time of maximum observed concentration sampled during a 
dosing interval
AUC last Area under the curve from the time of dosing to the last 
measurable concentration
AUC 0-infArea under the curve extrapola ted to infinity , calculated using the 
observed value of the last non- zero concentration

Shire CONFIDENTIAL Page 61
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
AUC 0-inf%extrap The percent of AUC 0-inf extrapolated, calculated by 
(1-AUC last/AUC 0-inf)*100
λzelimination rate in the terminal phase 
t1/2Terminal half -life
CL/F Apparent total body clearance following extravascular 
administration calculated as dose divided b y AUC 0-inf
Vz/F Apparent volume of distribution following extravascular 
administration calculated as CL /F divided by  λz
Tlag Delay  between the time of dosing an d time of appearance of drug 
(investigational) i
n plasma in the employ ed sampling scheme
In addition, dose- normalized (to 400 mg) AUC last, AUC 0-inf, and C maxwill be calculated for 
Japanese subjects. 
8.7.1.1 Statistical Analysis of Pharmacokinetic Parameters
Mari bavir C max, AUC last, and AUC 0-infwill be the primary  endpoints.  
 Individual concentrations and PK parameters (including 
dose-normalized) of maribavir and  will be listed and summarized by  maribavi r dose 
with descriptive statistics (number, arithmetic mean, standard deviation [SD], coefficient of 
variation [CV], median, minimum, maximum, geometric mean, and percent coefficient of 
variation (CV%) of geometric mean. The 95% CIs of the geometric means of Cmax, AUC last, and 
AUC 0-infparameters will be presented as well. Figures of individual and mean (±SD) maribavir 
concentration -
time profiles will be generated on linear and semi- log scales. The mean 
concentration -time profiles will be generated and display ed by overlay ing the Japane se cohort 
and Non -Hispanic Caucasian cohort. Figures of PK parameters and dose -normalized PK 
parameters vs. dose in Japanese subjects will be generated. Box -Whisker plots for selected PK 
parameter will be generated with Japanese cohort and Non -Hispanic Caucasian side by  side.  
In order to compare the PKs of maribavir between subjects of Japanese descent and matched 
non-Hispanic, Caucasian subjects, the differences of log -transformed PK parameters (AUC last, 
AUC 0-inf, and C max) from the maribavir 400 mg oral dose will be examined between cohorts 
using an anal ysis of variance model. The geometric mean ratio and its 90% CI  of PK parameters 
for Japanese descent vs. Caucasian will be provided from the model. In addition, the difference 
of log -transformed dose -normalized AUC last, AUC 0-inf, and C maxwill be examined between the 
Japanese cohort estimated at the 200 mg dose and the Non-
Hispanic Caucasian cohort estimated 
at the 400 mg dose, as well as between the Japanese cohort estimated at the 800 mg dose and the 
Non-Hispanic Caucasian cohort estimated at 400 mg dose, using an anal ysis of variance model. 
The geometric mean ratio and its 90% CI  will be provided from the model. Forest plots of 
geometric mean ratios for selected PK parameters between Japanese cohort vs. the Non- Hispanic 
Caucasian cohort at 400 mg will be generated.  

Shire CONFIDENTIAL Page 63
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Adverse events will be coded using the agreed -upon version of Medical Dictionary  for 
Regulatory  Activities, Version 23.0. or later. The number of events, incidence, and percentage of 
TEAEs will be calculated overall, by  system organ class, and b y PT. Treatment emergent 
adverse events will be further summarized b y severity and relationship to investigational 
product. Adverse events related to investigational product, AEs leading to withdrawa l, SAEs, 
and deaths will be similarly  summarized/listed.
8.9 Sample Size Calculation and Power Considerations 
The sample size consideration for the primary  objective of evaluating the PK profile of 
maribavir, administered as a single oral dose at 400 mg, betw een Japanese subjects and matched, 
healthy , adult, non -Hispanic, Caucasian subjects is based on feasibility  and comparable studies . 
A total of 24 subjects (12 subjects of Japanese descent and 12 matched, non -Hispanic, Caucasian 
subjects) will be targeted to be enrolled in the study .
Shire CONFIDENTIAL Page 64
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
9. REFERENCES
Avery , P. 2007. Management of late, recurrent, and resistant cy tomegalovirus in transplant 
patients. Transplant Rev, 21, 65-76.
Biron, K. K., Harvey , R. J., Chamberlain, S. C., Good, S. S., Smith, A . A., 3rd, Davis, M. G., 
Talarico, C. L., Miller, W. H., Ferris, R., Dornsife, R. E., Stanat, S. C., Drach, J. C., 
Townsend, L. B. & Koszalka, G. W. 2002. Potent and selective inhibition of human 
cytomegalovirus replication by  1263W94, a benzimidazole L -riboside with a unique 
mode of action. Antimicrob Agents Chemother, 46, 2365 -72.
Boeckh, M., Nichols, W. G., Papanicolaou, G., Rubin, R., Wingard, J. R. & Zaia, J. 2003. 
Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known 
challenges, and future strategies. Biol Blood Marrow Transplant, 9, 543- 58.
Chulay , J., Biron, K., Wang, L., Underwood, M., Chamberlain, S., Frick, L., Good, S., Davis, 
M., Harvey , R., Townsend, L ., Drach, J. & Koszalka, G. 1999. Development of novel 
benzimidazole riboside compounds for treatment of cy tomegalovirus disease. Adv Exp 
Med Biol, 458, 129-34.
de la Hoz, R. E., Stephens, G. & Sherlock, C. 2002. Diagnosis and treatment approaches of 
CMV infections in a dult patients. J Clin Virol, 25 Suppl 2, S1-12.
Drew, W. L., Miner, R. C., Marousek, G. I. & Chou, S. 2006. Maribavir sensitivity  of 
cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol, 37, 
124-7.
Farrugia, E. & Schwab, T. R. 1992. Management and prevention of cy tomegalovirus infection 
after renal transplantation. Mayo Clin Proc, 67, 879-
90.
Hodson, E. M., Jones, C. A., Webster, A. C., Strippoli, G. F., Barclay , P. G., Kable, K., 
Vimalachandra, D. & Craig, J. C. 2005. Ant iviral medications to prevent 
cytomegalovirus disease and earl y death in recipients of solid-organ transplants: a 
systematic review of randomised controlled trials. Lancet, 365, 2105-
15.
Kanj, S., Sharara, A., Clavien, P. & Hamilton, J. 1996. Cy tomegalovir us infection following 
liver transplantation: review of the literature. Clin Infect Dis, 22, 537-49.
Kern, E. R., Hartline, C. B., Ry bak, R. J., Drach, J. C., Townsend, L . B., Biron, K. K. & 
Bidanset, D. J. 2004. Activities of benzimidazole D -and L -ribonucleosides in animal 
models of cy tomegalovirus infections. Antimicrob Agents Chemother, 48, 1749 -
55.
Krosky , P., Baek, M. & Coen, D. 2003. The human cy tomegalovirus UL97 protein kinase, an 
antiviral drug target, is required at the stage of nuclear egress. JVirol, 77, 905 -14.
Legendre, C. & Pascual, M. 2008. I mproving outcomes for solid-
organ transplant recipients at 
risk from cy tomegalovirus infection: late -onset disease and indirect consequences. Clin 
Infect Dis, 46, 732-40.
Limay e, A. P., Corey , L., Koell e, D. M., Davis, C. L . & Boeckh, M. 2000. Emergence of 
ganciclovir -resistant cy tomegalovirus disease among recipients of solid -organ 
transplants. Lancet, 356, 645-9.
Ljungman, P., Deliliers, G. L ., Platzbecker, U., Matthes- Martin, S., Bacigalupo, A., Einse le, H., 
Ullmann, J., Musso, M., Trenschel, R., Ribaud, P., Bornhauser, M., Cesaro, S., Crooks, 
B., Dekker, A., Gratecos, N., Klingebiel, T., Tagliaferri, E., Ullmann, A. J., Wacker, P. & 
Cordonnier, C. 2001. Cidofovir for cy tomegalovirus infection and dise ase in allogeneic 
stem cell transplant recipients. The Infectious Diseases Working Part y of the European 
Group for Blood and Marrow Transplantation. Blood, 97, 388-92.
Shire CONFIDENTIAL Page 65
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Ljungman, P., Perez -Bercoff, L., Johnsson, J., Avetisy an, G., Sparrelid, E., Aschan, J., Barkholt, 
L., Larsson, K., Winiarski, J., Yun, Z. & Ringden, O. 2006. Risk factors for the 
development of cy tomegalovirus disease after allogeneic stem cell transplantation. 
Haematologica, 91, 78- 83.
Paya, C., Hermans, P., Wiesner, R., Ludwig, J., Smith, T., Rakela, J. & Krom, R. 1989. 
Cytomegalovirus hepatitis in liver transplantation: prospective anal ysis of 93 consecutive 
orthotopic liver transplantations. J Infect Dis, 160, 752 -8.
Pouria, S., State , O. I ., Wong, W. & Hendry , B. M. 1998. CMV infection is associated with 
transplant renal artery  stenosis. Qjm, 91, 185-9.
Razonable, R. R. & Emery , V. C. 2004. Management of CMV infection and disease in transplant 
patients. 27
-29 February  2004. Herpes, 11, 77-86.
Reusser, P., Einsele, H., Lee, J., Volin, L., Rovira, M., Engelhard, D., Finke, J., Cordonnier, C., 
Link, H., Ljungman, P. & Infectious Diseases Working Part y of the European Group for 
Blood and Marrow Transplantation 2002. Randomized multicenter trial of foscarnet 
versus ganciclovir for preemptive therap y of cy tomegalovirus infection after allogeneic 
stem cell transplantation. Blood, 99, 1159-64.
Richardson, W. P., Colvin, R. B., Cheeseman, S. H., Tolkoff
-Rubin, N. E., Herrin, J. T., Cosimi, 
A. B. , Collins, A. B., Hirsch, M. S., McCluskey , R. T., Russell, P. S. & Rubin, R. H. 
1981. Glomerulopathy  associated with cy tomegalovirus viremia in renal allografts. N 
Engl J Med, 305, 57-63.
Rubin, R. H. 1989. The indirect effects of cy tomegalovirus infectio n on the outcome of organ 
transplantation. Jama, 261, 3607 -9.
Salzberger, B., Bowden, R. A., Hackman, R. C., Davis, C. & Boeckh, M. 1997. Neutropenia in 
allogeneic marrow transplant recipients receiving ganciclovir for prevention of 
cytomegalovirus disease : risk factors and outcome. Blood, 90, 2502-8.
Singh, N., Wannstedt, C., Key es, L., Wagener, M. M., de Vera, M., Cacciarelli, T. V. & 
Gayowski, T. 2004. Impact of evolving trends in recipient and donor characteristics on 
cytomegalovirus infection in liver transplant recipients. Transplantation, 77, 106 -10.
Williams, S. L ., Hartline, C. B., Kushner, N. L., Harden, E. A., Bidanset, D. J., Drach, J. C., 
Townsend, L. B., Underwood, M. R., Biron, K. K. & Kern, E. R. 2003. In vitro activities 
of benzimidazole D -and L -ribonucleosides against herpesviruses. Antimicrob Agents 
Chemother, 47, 2186-
92.
Winston, D. J., Wirin, D., Shaked, A. & Busuttil, R. W. 1995. Randomised comparison of 
ganciclovir and high -dose acy clovir for long -term cy tomegalovirus prophylaxis in l iver-
transplant recipients. Lancet, 346, 69-74.
Wolf, D., Courcelle, C., Prichard, M. & Mocarski, E. 2001. Distinct and separate roles for 
herpesvirus -conserved UL97 kinase in cy tomegalovirus DNA s ynthesis and 
encapsidation. 
Proc Natl Acad Sci U S A, 98, 1895-900.
Shire CONFIDENTIAL Page 67
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Appendix 1Regulatory, Ethical, and Study Oversight Considerations
Appendix 1.1 Regulatory and Ethical Considerations
This study  is conducted in accordance with current applicable regulations including ICH E6, EU 
Directive 2001/20/EC, and all updates, as well as local ethical and legal requirements. 
Compliance with these regulati ons and guidelines also constitutes compliance with the ethical 
principles described in the Declaration of Helsinki.
The name and address of each third -party vendor (eg, CRO) used in this study  will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
Appendix 1.2 Sponsor’s Responsibilities
Good Clinical Practice Compliance
The study  sponsor and any  third party  to whom aspects of the study  management or monitoring 
have been delegated will undertake their assigned roles for this study  in compliance with all 
applicable industry  regulations, current ICH GCP guideline E6 (1996) , EU Directive 2001/20/EC 
Guidelines, as well as all applicable national and local laws and regulations.
Visits to sites are conducted by  representatives of the study  sponsor and/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and CRFs in accordance with current GCP and the respective local and 
(inter)national government regulations and guidelines . Records and data may  additionall y be 
reviewed b y auditors or by  regulatory  authorities.
The sponsor ensures that local regulatory  authority requirements are met before the start of the 
study . The sponsor (or a nominated designee) is responsible for the p reparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior to release of IP for 
shipment to the site.
Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on applicable websites. 
Information included in clinical study  registries may  include participating investigators’ names 
and contact information.
The timing for stud y registration and results summary posting must be in accordance with 
applicable local and national requirements.
Shire CONFIDENTIAL Page 68
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Submission of Summary of Clinical Study Report to Competent Authorities of Member 
States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent authority  of the 
member state(s) c oncerned as required by  regulatory  requirement(s) and to comply  with the 
Community  guideline on GCP. This requirement will be fulfilled within 6 months of study  
completion date for pediatric studies and within 1 y ear for non-pediatric studies as per guidan ce. 
Study Suspension, Termination, and Completion
The sponsor may  suspend or terminate the study , or part of the study , at any  time for any  reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and Institutional Review Boards (IRBs)/Ethics committees (ECs) are notified as 
appropriate. Additionally, the discontinuation of a registered clinical study  which has been 
posted to a designated public website will be updated accordingl y.
Appendix 1.3 Investigator’s Responsibilities
Good Clinical Practice Compliance
The investigator must undertake to perform the study  in accordance with ICH GCP Guideline E6 
(1996) and E6 R2 (2017) , EU Directive 2001/20/EC, and applicable regulatory  requirements and 
guideli nes.
It is the investigator’s responsibility  to ensure that adequate time and appropriately  trained 
resources are available at the site prior to commitment to participate in this study . The 
investigator should also be able to estimate or demonstrate a pote ntial for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant study -related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifications necessary  to demonstrate such 
qualification. Curricula vitae for investigators and sub- investigators are provided to the study  
sponsor (or designee) before starting the study .
If a potential research subject has a primary  care phy sician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study .
Agreement with the final clinical study  report is documented by  the signed and dated signature 
of the principal investigator, in compliance with Directive 2001/83/EC as amended b y Directive 
2003/63/EC and I CH Guidance E3 ( 1995 ).
Shire CONFIDENTIAL Page 69
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Protocol Adherence and Investigator Agreement
The investigator and an y sub-investigators must adher e to the protocol as detailed in this 
document. The investigator is responsible for enrolling only  those subjects who have met 
protocol eligibility  criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigator suspends or terminates the study  at their site, the investigator will promptly  
inform the sponsor and the I RB/EC and provide them with a detailed written explanation. The 
investigator will also return all IP, containers, and other study  materials to the sponsor. Upon 
study  completion, the investigator will provide the sponsor, I RB/EC, and regulatory  agency  with 
final reports and summaries as required by  (inter)national regulations.
Communication with l ocal I RBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  the sponsor, applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator according to national provisi ons and 
will be documented in the investigator agreement.
Documentation and Retention of Records
Case Report Forms
Case report forms are supplied by  the CRO and should be handled in accordance with 
instructions from the sponsor.
The investigator is respons ible for maintaining adequate and accurate medical records from 
which accurate information is recorded onto CRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
complete d by the investigator or designee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly  onto the 
CRF.
All data sent to the sponsor must be endorsed b y the investigator.
The CRA/study  monit or will verify  the contents against the source data per the monitoring plan. 
If the data are unclear or contradictory , queries are sent for corrections or verification of data.
All data sent to the sponsor must be endorsed b y the investigator.
Once the CRA /study  monitor has verified the contents of the completed CRF pages against the 
source data, the duplicate pages are retrieved and forwarded to the study  sponsor (or designee) 
for data entry . If the data are unclear or contradictory, queries are sent for c orrections or 
verification of data.
Shire CONFIDENTIAL Page 70
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include, but are not limited to: 
subject’s medical file and original clinical laboratory  repo rts
All key  data must be recorded in the subject’s source documents.
The investigator must permit authorized representatives of the sponsor, the respective national, 
local, or foreign regulatory  authorities, the IRB/EC, and auditors to inspect facilities a nd to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study  monitor (and auditors, IRB/EC or regulatory  inspectors) may  check the CRF 
entries against the source documents. The consent form includes a state ment by  which the 
subject agrees to the monitor/auditor from the sponsor or its representatives, national or local 
regulatory  authorities, or the I RB/EC, having access to source data (eg, subject’s medical file, 
appointment books, original laboratory  repor ts, X -rays etc.). 
These records must be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authorized representative of any  regulatory  agency  (eg, the United States 
Food and Drug Administration [US FDA], Euro pean Medicines Agency  [EMA], United 
Kingdom Medicines and Healthcare products Regulatory  Agency  UKMHRA) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the spo nsor.
Audit/Inspection
To ensure compliance with relevant regulations, data generated b y this study must be available 
for inspection upon request by  representatives of, for example, the US FDA (as well as other US 
national and local regulatory  authorities), the EMA, the Medicines and Healthcare products 
Regulatory  Agency , other regulatory  authorities, the sponsor or its representatives, and the 
IRB/EC for each site.
Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study  and for 1 year 
after, whereb y the outcome of the study  could be influenced by  the value of the compensation for 
conducting the study , or other pay ments the investigator received from the sponsor. The 
following information is co llected: an y significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary interest in I P; any  significant equit y interest 
in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) (1998).
Shire CONFIDENTIAL Page 71
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Compliance to all Local, State, and National Controlled- substance Biohazard and 
Infectious Disease Regulations and Legislation
When using controlled substances, biohazardous material, or substances for infectious diseases, 
the investigator must at all times comply  with all local, state, and national laws pertaining to 
registration and reporting with the appropriate regulatory  body  and control and handling of such 
substances.
Appendix 1.4 Ethical Considerations
Informed Consent
It is the responsibility  of the investigator to obtain written informed consent from all study  
subjects prior to an y study -related procedures including screening assessments. All consent 
documentation must be in ac cordance with applicable regulations and GCP. Each subject or the 
subject’s legall y-authorized representative, as applicable, is requested to sign and date the subject 
informed consent form or a certified translation if applicable, after the subject has re ceived and 
read (or been read) the written subject information and received an explanation of what the study 
involves, including but not limited to: the objectives, potential benefits and risk, inconveniences, 
and the subject’s rights and responsibilities. A copy of the informed consent documentation (ie, a 
complete set of subject information sheets and fully executed signature pages) must be given to 
the subject or the subject’s legally  authorized representative, as applicable. This document may  
require tr anslation into the local language. Signed consent forms must remain in each subject’s 
study  file and must be available for verification at any  time.
The principal investigator provides the sponsor with a cop y of the consent form which was 
reviewed b y the I RB/EC and which received their favorable opinion/approval. A copy  of the 
IRB/EC’s written favorable opinion/approval of these documents must be provided to the 
sponsor, prior to the start of the study  unless it is agreed to and documented (abiding by  
regul atory  guidelines and national provisions) prior to study  start that another part y (ie, sponsor 
or coordinating principal investigator) is responsible for this action. Additionally, if the IRB/EC 
requires modification of the sample subject information and c onsent document provided by  the 
sponsor, the documentation supporting this requirement must be provided to the sponsor.
Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator to submit this pro tocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
information and all ty pes of subject recruitment information to the I RB/EC for review, and all 
must be approved prior to site initiation.
The applicant fo r an EC opinion can be the sponsor or the investigator for sites within the EU; 
for multicenter studies the applicant can be the coordinating principal investigator or sponsor, 
according to national provisions.
Responsibility  for coordinating with IRBs/ECs is defined in the clinical trial agreement.
Shire CONFIDENTIAL Page 72
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Investigational product supplied will not be released until the sponsor has received written 
IRB/EC approval.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any  
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safet y issue. If required by local law, substantial amendments to the protocol must also 
be approved b y the appropriate regulatory  agency  prior to implementation.
For s ites outside the EU, the investigator is responsible for keeping the I RB/EC appraised of the 
progress of the stud y and of an y changes made to the protocol, at least annually  or more 
frequentl y in accordance with the requirements, policies, and procedures e stablished by  the 
IRB/EC. This can be the responsibility  of the sponsor or investigator for sites within the EU; or 
for multicenter studies, the coordinating principal investigator, according to national provisions. 
The investigator must also keep the loca l IRB/EC informed of any  serious and significant AEs as 
required b y IRB/EC procedures.
Privacy and Confidentiality
All US-based sites and laboratories or entities providing support for this study , must, where 
applicable, compl y with theHealth Insurance Po rtability  and Accountability  Act (HIPAA) of 
1996. A site that is not a covered entity  as defined by  HIPAA must provide documentation of 
this fact to the sponsor.
The confidentialit y of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representatives’ 
reviews their medical records and data collected during the stud y. These records and data may, in 
addition, be reviewed b y others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may  develop, register, or 
market maribavir; national or local regulatory  authorities; and the I RB/EC which gave approval 
for the stud y to proceed. The sponsor and/or its representatives accessing the records and data 
will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentialit y of subjects’ identities.
Subjects are assigned a unique identify ing number.
The results of studies containing subjects’ unique identify ing number, relevant medical records, 
and possibly  initials and dates of birth, where allowed per local law, may be transfer red to, and 
used in, other countries which may  not afford the same level of protection that applies within the 
countries where this study is conducted. The purpose of an y such transfer would include: to 
support regulatory  submissions, to conduct new data a nalyses to publish or present the study  
results, or to answer questions asked by  regulatory or health authorities.
Shire CONFIDENTIAL Page 73
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Study Results / Publication Policy
The term “Publication” shall mean an y paper, article, manuscript, report, poster, internet posting, 
presen tation slides, abstract, outline, video, instructional material, presentation (in the form of a 
written summary ), or other public disclosure of the study  results, in printed, electronic, oral, or 
other form. The parties understand and agree that participat ion in the study  may  involve a 
commitment to publish the data from all sites participating in the study  in a cooperative 
publication with other investigators prior to publication or oral presentations of the study  results 
on an individual basis. The site a grees not to publish or present the site’s study  results until such 
time as either the aggregate multi- site study  results are published in a cooperative publication or 
for a period of one (1) year after termination or completion of the study  at all partici pating sites, 
whichever shall first occur. After that time, the site may  publish the site’s study  results in 
scientific journals or present the study  results at symposia or other professional meetings in 
accordance with the following provisions:
If the study  is part of a multicenter study , the first publication of the study  results shall be made 
by the sponsor in conjunction with the sponsor’s presentation of a joint, multicenter publication 
of the compiled and analy zed study  results. If such a multicenter publication is not submitted to a 
journal for publication by  the sponsor within an 18-month period after conclusion, abandonment, 
or termination of the study
 at all sites, or after the sponsor confirms there shall be no multicenter 
study  publication of the study  results, an investigator may individuall y publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single site data being presented.
At le ast sixty  (60) day s prior to submitting an abstract, manuscript, or other document for 
publication, a cop y of the proposed publication will be provided to the sponsor by the site for 
review. Upon the sponsor’s request, the site agrees to remove an y and all confidential 
information (expressly  excluding study  results) identified in the publication and to delay  such 
submission or presentation for an additional sixty  (60) day  period in order to allow the sponsor 
time to file any  patent application(s). All publi cations of the study  results shall appropriatel y 
reference the multi- site study  publication, if an y, or the fact that the study results are a subset of 
data resulting from a larger multi- site study .
Shire is committed to transparent dissemination of all scientific, technical and medical 
manuscripts generated from Shire -supported research. Therefore, after January  1, 2018, Shire 
will require the submission of all Shire-supported research manuscripts to journals that offer 
public availability  via Open Access (including publisher platforms/repositories and 
self-archiving). Open Access refers to the free at point of entry , online availability  of published 
research output with, where available, rights of re- use according to an End User License.
Unless otherwise required by  the journal in which the publication appears, or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
(ICMJE) Recommendation for the Conduct, Reporting, Editing and Publication of Scholarl y 
Work in Medical journals. Participation as an investigator does not confer any rights to 
authorship of publications.
Shire CONFIDENTIAL Page 74
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Appendix 2 Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow -Up, and R eporting
Appendix 2.1 Adverse Event Definitions
An AE is an y untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily have a causal relationship with this I P or 
medicinal product. A n AE can therefore be any  unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease temporall y associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational)
product (ICH Guidance E2A 1995).
Treatment -emergent Adverse Event
A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment 
with an I P or medicinal product or any  existing event that worsens in either intensity  or 
frequency  following exposure to the IP or medicinal product. 
Serious A dverse Event 
An SAE is any  untoward medical occurrence (whether considered to be related to I P or not) that 
at an y dose:
 Results in death
 Is life -threatening. Note: The term ‘life-
threatening’ in the definition of “serious” 
refers to an event in which the subject was at risk of death at the time of the event; it 
does not refer to an event which hy potheticall y might have caused death if it was 
more severe.
 Requires inpatient hospitalization or prolongation of existing hospitalization. Note: 
Hospitalizations , that are the result of elective or previously scheduled investigations 
procedures or surgery  for pre -existing conditions andhave not worsened after 
initiation of treatment, should not be classified as SAEs. For example, an admission 
for a previously  scheduled ventral hernia repair would not be classified as an SAE; 
however, complication(s) resulting from a hospitalization for an elective or 
previously  scheduled surgery  that meet(s) serious criteria must be reported as 
SAE(s).
 Results in persistent or sig nificant disability /incapacity
 Results in a congenital abnormality /birth defect
 Is an important medical event. Note: I mportant medical events that may not result in 
death, be life -threatening, or require hospitalization may  be considered an SAE 
when, based upon appropriate medical judgment, they  may  jeopardize the subject 
and may  require medical or surgical intervention to prevent 1 of the outcomes listed 
in this definition. Examples of such medical events include bronchospasm associated 
with anaph ylaxisrequiring intensive treatment in an emergency  room or at home; 
blood dy scrasias or convulsions that do not result in inpatient hospitalization; or the 
development of drug dependency  or drug abuse.
Shire CONFIDENTIAL Page 75
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Unexpected Adverse Event
An unexpected adverse event is an AE whose nature, severity , specificit y, or outcome is not 
consistent with the term, representation, or description used in the IB. “Unexpected” also refers 
to the AEs that are mentioned in the maribavir IB and/or prescribing information as occurring 
with a c lass of drugs or as anticipated from the pharmacological properties of the product, but are 
not specificall y mentioned as occurring with the particular product under investigation. 
The expectedness of AEs will be determined b y the sponsor using the IB and/or prescribing 
information as the Reference Safet y Information. This determination will include considerations 
such as the number of AEs previously  observed, but not on the basis of what might be 
anticipated from the pharmacological properties of a produc t.
Suspected Unexpected Serious Adverse Reaction 
A Suspected Unexpected Serious Adverse Reaction (SUSAR) is defined as any  suspected 
adverse reaction to study  treatment (ie, including active comparators) that is both serious and 
unexpected. 
The event(s) must meet all of the following:
 Suspected adverse reaction
 Serious
 Unexpected
 Assessed as related to study  treatment
Unanticipated Adverse Device Effect 
An unanticipated adverse device effect is an y serious adverse effect on health or safet y or an y 
life-threatening problem or death caused by , or associated with, a device, if that effect, problem, 
or death was not previously  identified in nature, severit y, or degree of incidence in the stud y 
protocol or product labeling; or an y other unanticipated ser ious problem associated with a device 
that relates to the rights, safet y, or welfare of subjects.
Clinical Laboratory and Other Safety Assessment
A change in the value of a clinical laboratory  parameter, vital sign measure, or ECG assessment 
can represent an AE if the change is clinically relevant or if, during administration of I P, a shift 
of a parameter is observed from a value in the normative range to a value that is outside the 
normal range and considered clinically  significant, or a further waning of an alread y clinically  
significant value. When evaluating such changes, the extent of deviation from the reference 
range, the duration until return to the reference range, either while continuing administration or 
after the end of administration with the I P, and the range of variation of the respective parameter 
within its reference range, should also be considered.
Shire CONFIDENTIAL Page 76
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
If, at the end of the treatment phase, there are abnormal clinical laboratory  (such as hematology  
panel or clinical chemistry  panel), vital sign, or ECG values which were not present at the 
pretreatment evaluation observed closest to the start of study  treatment, further investigations 
should be performed until the values return to within the reference range or until a plausible 
explanation (eg, c oncomitant disease or expected disease evolution) is found for the abnormal 
values.
The investigator should assess, based on the above criteria and the clinical condition of the 
subject, whether a change in a clinical laboratory  value, vital sign, or ECG p arameter is clinicall y 
significant and represents an AE.
Appendix 2.2 Collection of Adverse Events
All AEs /SAEs are collected from the time the informed consent is signed until the defined 
follow -up period stated in Section 7.1.4. This includes events occu rring during the screening 
phase of the stud y, regardless of whether or not IP is administered. 
All AEs/SAEs must be followed to closure (the subject’s health has returned to his/her baseline 
status or all variables have returned to baseline), regardless of whether the subject is still 
participating in the stud y. Closure indicates that an outcome is reached, stabilization achieved 
(the investigator does not expect any  further improvement or worsening of the event), or the 
event is otherwise explained.
Appe ndix 2.3 Assessment of Adverse Events
Severity Categorization
The severit y of AEs must be recorded during the course of the event including the start and stop 
dates for each change in severity. An event that changes in severity is captured as a new event. 
Worsening medical conditions, signs or sy mptoms present prior to initiation of I P, must be 
recorded as new AEs.
For example, if a subject reports mild intermittent dy spepsia prior to initiation of dosing with the 
IP, and the d yspepsia becomes severe and more frequent after first dose of a new AE of severe 
dyspepsia (with the appropriate date of onset) should be documented in the source.
The medical assessment of severit y is determined by using the following definitions:
Mild : A type of AE that is usually transient and may  require only  minimal treatment or 
therapeutic intervention. The event does not generally  interfere with usual 
activities of daily  living.
Moderate :A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily  living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe : A type of AE that interrupts usual activities of daily  living, or significantl y affects 
clinical statu s, or may  require intensive therapeutic intervention.
Shire CONFIDENTIAL Page 77
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Relationship Categorization
A phy sician/investigator must make the assessment of relationship to I P for each AE. The 
investigator should decide whether, in his or her medical judgment, there is a reason able 
possibility  that the event may  have been caused by the I P. If there is no valid reason for 
suggesting a relationship, then the AE should be classified as “not related”. Otherwise, if there is 
any valid reason, even if undetermined or untested, for sus pecting a possible cause -and-effect 
relationship between the IP and the occurrence of the AE, then the AE should be considered 
“related”. The causalit y assessment must be documented in the source.
The following additional guidance may  be helpful:
Term Relationship Definition
RelatedThe temporal relationship between the event and the administration of the IP is 
compelling and/or follows a known or suspected response pattern to that product, and 
the event cannot be explained by the subject’s medical con dition, other therapies, or 
accident.
Not RelatedThe event can be readily explained by other factors such as the subject’s underlying 
medical condition, concomitant therapy, or accident and no plausible temporal or 
biologic relationship exists between the IP and the event.
Outcome Categorization
The outcome of AEs must be recorded in the source during the course of the study . Outcomes are 
as follows:
Fatal
Not Recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved With Sequelae
Recovering/Resolvi ng
Unknown.
If applicable, action taken (ie, dose increased, dose not changed, dose reduced, drug interrupted, 
drug withdrawn, not applicable, or unknown) will also be recorded on the AE CRF. 
Appendix 2.4 Safety Reporting
Reference Safety Information
The reference for safet y information for this study  is the maribavir IB, which the sponsor has 
provided under separate cover to all investigators.
Shire CONFIDENTIAL Page 78
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Reporting Procedures
All initial and follow -up SAE reports must be reported by  the investigator to the Shire Global 
Drug Safet yDepartment, the CRO, and Shire Medical Monitor within 24 hours of becoming 
aware of the event. Note: The 24- hour reporting requirement for SAEs does not apply  to reports 
of abuse, misuse, overdose, or medication errors ( Appendix 2.9) unless they result in an SAE.
The investigator must complete, sign, and date the Shire “Clinical Study  Serious Adverse Event 
for SAEs and Non -serious AEs as Required by  Protocol” Form and verify  the accuracy  of the 
info
rmation recorded on the form with the corresponding source documents (Note: Source 
documents are not to be sent unless requested), and fax or e- mail the form to the Shire Global 
Drug Safet y Department. A cop y of the Shire Clinical Study Serious Adverse Eve nt Form for 
SAEs and Non- serious AEs as Required b y Protocol (and an y applicable follow -up reports) must 
also be sent to the CRO and Shire Medical Monitor using the details specified in the emergency  
contact information section of the protocol.
Appendix 2.5 Serious Adverse Event Collection Time Frame
All SAEs (regardless of relationship to IP) are collected from the time the subject signs the 
informed consent until the defined follow- up period stated in Section 7.1.4, and must be reported 
to the Shire Globa l Drug Safety Department and the CRO and Shire Medical Monitor within 
24hours of the first awareness of the event.
In addition, any  SAE(s) considered “related” to the I P and discovered by  the investigator at any  
interval after the stud y has completed must be reported to the Shire Global Drug Safet y
Department within 24 hours of the first becoming aware of the event.
Appendix 2.6 Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets seriousness cri teria. The 
resolution date is the date the event no longer meets seriousness criteria, the date the s ymptoms 
resolve, or the event is considered chronic. In the case of hospitalizations, the hospital admission 
and discharge dates are considered the onset a nd resolution dates, respectively .
In addition, any  signs or sy mptoms reported by the subject after signing the informed consent 
form, or leading up to the onset date of the SAE, or following the resolution date of the SAE, 
must be recorded as an AE, if appropriate.
Appendix 2.7 Fatal Outcome
Any SAE that results in the subject’s death ( eg, the SAE was noted as the primary  cause of 
death) must have fatal checked as an outcome with the date of death recorded as the resolution 
date. For all other events ongoing at the time of death that did not contribute to the subject’s 
death, the outcome should be considered not resolved, without a resolution date recorded.
Shire CONFIDENTIAL Page 79
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
For an y SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another IP action was previously  taken (eg, drug interrupted, reduced, withdrawn), the action 
taken with the I P should be recorded as “dose not changed” or “not applicable” (if the subject 
never received IP or it is a single dose study ). The IP action of wit hdrawn should not be selected 
solely  as a result of the subject’s death.
Appendix 2.8 Pregnancy
All pregnancies are to be reported from the time informed consent is signed until the defined 
follow -up period stated in Section 7.1.4.
Any report of pregnancy  for an y female stud y participant or the partner of a male study 
participant must be reported within 24 hours to the Shire Global Drug Safety  Department using 
the Shire Investigational and Marketed Products Pregnancy  Report Form. A copy  of the Shire 
Investi gational and Marketed Products Pregnancy  Report Form (and any  applicable follow -up 
reports) must also be sent to the CRO and Shire Medical Monitor using the details specified in 
the emergency  contact information section of the protocol. The pregnant female study  participant 
must be withdrawn from the study .
In addition to the above, if the investigator determines that the pregnancy  meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study  Serious Adverse Event and 
Non-serious AEs Required by  the Protocol Form as well as the Shire Investigational and 
Marketed Products Pregnancy  Report Form. The test date of the first positive serum/urine 
β
-HCG test or ultrasound result will determine the pregnancy  onset date.
Pregnancy  complications such as spontaneous abortion/miscarriage, elective abortion or 
congenital abnormalit y are considered SAEs and must be reported using the Shire Clinical Study  
Serious Adverse Event and Non- serious AEs Required by  the Protocol Form. 
Every  effort should be 
made to gather information regarding the pregnancy  outcome and 
condition of the infant. It is the responsibility  of the investigator to obtain this information within 
30calendar day s after the initial notification and approximately  30 calendar day s and 1 year 
post-partum.
Appendix 2.9 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the sponsor 
according to the SAE reporting procedure whether or not they  result in an AE/SAE as described 
in Appendix 2.4. 
Note: The 24- hour reporting requirement for SAEs does not apply to reports of abuse, misuse, 
overdose, or medication errors unless these result in an SAE. 
The categories below are not mutually  exclusive; the event can meet more than 1 category .
Shire CONFIDENTIAL Page 80
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Abuse –Persistent or sporadic intentional intake of I P when used for a non -medical purpose 
(eg, to alter one’s state of consciousness or get high) in a manner that may  be detrimental to 
the individual an d/or society
Misuse –Intentional use of I P other than as directed or indicated at any  dose (Note: this 
includes a situation where the I P is not used as directed at the dose prescribed by  the 
protocol)
Overdose –Intentional or unintentional intake of a dose of IP higher than the 
protocol -prescribed dose
Medication Error –An error made in prescribing, dispensing, administration, and/or use of 
an IP. Medication errors should be collected/reported for all products under investigation. 
The administration and/or use of the unassigned treatment, or the administration and/or use 
of an expired IP is/are alway s reportable as a medication error.
Cases of subjects missing doses of the IP should be reported as missed dose.
Appendix 2.10 Urgent Safety Measures
An urgent safet y measure is an immediate action taken, which is not defined by the protocol, in 
order to protect subjects participating in a clinical trial from immediate harm, these do not 
constitute de facto deviatio n from the protocol. Urgent safet y measures may be taken b y the 
sponsor or clinical investigator, and may  include any  of the following:
Immediate change in study  design or stud y procedures
Temporary  or permanent halt of a given clinical trial or trials
Any other immediate action taken in order to protect clinical trial participants from 
immediate hazard to their health and safet y
The investigator may  implement urgent safety  measures to protect study  subjects from 
immediate hazard to their health or safet y. The measures should implement immediately  and 
does not require prior authorization from the sponsor. In the event(s) of an apparent direct hazard 
to the subject, the investigator will notify  the sponsor immediately  by phone and confirm 
notification to the sponsor in writing as soon as possible, and within 1 calendar day after the 
change is implemented. The sponsor will also ensure the responsible I RB(s)/EC(s) and relevant 
competent authorit y(s) are notified of the urgent safet y measures taken in such cases according to 
local regulations. 
Shire CONFIDENTIAL Page 81
TAK -620-1020 Protocol Amendment 1
Maribavir 08 Jul 2020
Appendix 2.11 Regulatory Agency, Institutional Review Board, Ethics Committee, and 
Site Reporting
The sponsor is responsible for notify ing the relevant regulatory  authorities, IRBs and ECs of 
related, unexpected SAEs.
In ad dition, the sponsor is responsible for notify ing active sites of all related, unexpected SAEs 
occurring during all interventional studies across the TAK- 620 program. 
The investigator is responsible for notify ing the local IRB/EC of SAEs or significant saf ety 
findings, or the relevant local regulatory  authorit y of all SAEs that occur at his or her site as 
required b y IRB/EC procedures.